METTL3 inhibitor compounds

Abstract

The present invention relates to compounds of formula (I): XYZ(I), where X, Y and Z are as defined herein, as inhibitors of METTL3 (N6-adenosine methyltransferase 70 kDa subunit) enzyme activity. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative disorders such as cancer and autoimmune diseases and other diseases in which METTL3 activity is implicated.

Description

[Technical Field]

[0001] The present invention relates to certain compounds that function as inhibitors of METTL3 (N6-adenosine methyltransferase 70 kDa subunit) activity. The invention also relates to methods for making these compounds, pharmaceutical compositions containing them, and their use in the treatment of proliferative disorders such as cancer, autoimmune, neurological, infectious and inflammatory diseases, and other diseases or conditions in which METTL3 activity is implicated. [Background technology]

[0002] N6-methyladenosine (m6A) is the most common and abundant covalent modification of messenger RNA and is regulated by the "writers," "erasers," and "readers" of this marker (Meyer & Jaffrey 2014, Niu Y et al., 2013, Yue et al., 2015). Approximately 0.1–0.5% of all mRNA adenosines are modified m6A (Li Y et al., 2015). In vitro data have shown that m6A affects fundamental aspects of mRNA biology, primarily mRNA expression, splicing, stability, localization, and translation (Meyer et al., 2015; Sledz & Jinek 2016). The m6A modification is tissue-specific, with significant variability in its occurrence profile in non-diseased tissues (e.g., brain, heart, kidney) and diseased tissues and cells (lung, kidney, breast, and leukemic cancer cells) (Meyer et al., 2012).

[0003] The m6A modification and its erasers, such as FTO, ALKBH5, methyltransferase-like 3 (METTL3) and METTL14, and writers, are associated with major diseases such as solid organ cancers, leukemia, type 2 diabetes, neuropsychiatric and behavioral disorders, and depressive disorders (Chandola et al., 2015; Koranda et al., 2018).

[0004] The RNA methyltransferase METTL3 is the major, but not the only, enzyme catalyzing the m6A modification of RNA. It exists as a heterotrimeric complex with METTL14 (Liu et al., 2014, Wang et al., 2016) and Wilms' tumor-associated protein (WTAP) (Ping et al., 2014). Catalytic activity resides in METTL3, which transfers a methyl group from the cofactor S-adenosylmethionine to the substrate RNA, while METTL14 facilitates substrate RNA binding. WTAP localizes the complex to specific nuclear regions and also localizes the RNA substrate to the complex (Wang X et al., 2016).

[0005] METTL3 has been reported to play a role in many aspects of cancer progression (Fry et al., 2018). Genetic knockdown of METTL3 in lung cancer cell lines (A549, H1299, and H1792) and HeLa cells resulted in reduced proliferation, survival, and invasiveness of human lung cancer cells (Lin S et al., 2016). METTL3 is significantly upregulated in human bladder cancer (Cheng et al., 2019). Knockdown of METTL3 dramatically reduced the proliferation, invasiveness, and survival of bladder cancer cells in vitro and their tumorigenicity in vivo. Further direct targets of METTL3-mediated m6A modification were identified: AF4 / FMR2 family member 4 (AFF4), two key regulators of the NF-κB pathway (IKBKB and RELA), and MYC. In renal cancer cell lines (CAK-1, CAK-2, and ACHN), gene knockdown reduces cell proliferation via the phosphatidinylinositol 3-kinase (PI3K) / AKT / mammalian target of rapamycin (mTOR) signaling pathway (Li X et al., 2017).

[0006] Recently, Barbieri et al. (2017) defined a set of RNA-modifying enzymes required for AML leukemia and identified a key leukemia pathway for the METTL3 RNA methyltransferase. In this pathway, METTL3 stably recruits the transcription factor CEBPZ via CCAAT boxes that bind to the promoters of a specific set of active genes, resulting in m6A methylation of the respective mRNAs and increased translation. One key target is SP1, an oncogene in several cancers that controls c-MYC expression. Consistent with these findings, it has been reported that METTL3 can co-transcriptionally methylate its targets.

[0007] The pathway described by Barbieri et al. is important in AML leukemia because three of its components are required for AML cell proliferation: (i) the m6A RNA methyltransferase METTL3; (ii) the transcription factor CEBPZ, which targets this enzyme to promoters; and (III) SP1, whose translation depends on the m6A modification by METTL3. Together, Barbieri et al. define METTL3 enzymatic activity as a potential new target for the treatment of AML.

[0008] Another independent study reported that METTL3 plays an essential role in regulating myeloid differentiation of normal hematopoietic and leukemic cells in mammals (Vu et al., 2017). Forced expression of wild-type METTL3, but not mutant METTL3 (defective in enzymatic activity), significantly promoted cell proliferation and inhibited cell differentiation of human umbilical cord blood-derived CD34+ hematopoietic stem / progenitor cells (HSPCs). Genetic knockdown of METTL3 had the opposite effect. METTL3 is more highly expressed in AML compared with normal HSPCs or other types of cancer. Knockdown of METTL3 in human AML cell lines significantly induced cell differentiation and apoptosis in mice xenografted with MOLM-13 AML cells, inhibiting leukemia progression. The biological function of METTL3 may contribute to promoting the translation of mRNA targets such as MYC, BCL-2, and PTEN in an m6A-dependent manner.

[0009] Recently, METTL3-mediated m6A modification has been shown to play an important role in T cell homeostasis and signal-dependent induction of mRNA decay in CD4+ T cell lineages (Li et al., 2017). Loss of METTL3 in mouse T cells disrupts T cell homeostasis and differentiation. In a lymphopenic mouse adoptive transfer model, naive Mettl3-deficient T cells failed to undergo homeostatic proliferation and remained naive for up to 12 weeks, thereby preventing colitis. Consistent with these observations, mRNAs of the SOCS family genes encoding the STAT signaling inhibitor proteins SOCS1, SOCS3, and CISH, marked by m6A, exhibited slower mRNA decay and increased mRNA and protein expression levels in Mettl3-deficient naive T cells. This increased SOCS family activity consequently inhibited IL-7-mediated STAT5 activation and homeostatic T cell proliferation and differentiation. Thus, METTL3-mediated m6A methylation has a critical role for the inducible degradation of Socs mRNA in response to IL-7 signaling to reprogram naive T cells for proliferation and differentiation.

[0010] Recent studies have revealed that depletion of METTL3 leads to altered growth of various viruses (Winkler et al.). Following viral infection or stimulation of cells with inactivated virus, deletion of the m6A "writer" METTL3 resulted in increased induction of interferon-stimulated genes. As a result, the growth of various viruses was suppressed in an interferon signaling-dependent manner. Significantly, IFN-γ mRNA was m6A-modified and stabilized after METTL3 suppression. m6A functions as a negative regulator of the interferon response by directing rapid turnover of interferon mRNA, thereby promoting viral growth. Therefore, METTL3 inhibitors may offer a novel therapeutic approach for a range of infectious and inflammatory diseases. [Prior art documents] [Non-patent literature]

[0011]

Outline Building1

Outdoor Tool2

Outdoor Tools3

Outdoor Tools 4

Direct Environment 5

Outdoor Configuration 6

Direct Environment 7

Outdoor Tools 8

Outdoor Tools9

Outdoor Tools 10

Outdoor Content11

Outdoor Tools 12

Outdoor Content13

Outdoor Tools 14

Outdoor Tools 15

Outdoor Content 16

Outdoor Track 17

[0012] An object of the present invention is to provide an agent that inhibits METTL3 activity. Summary of the Invention

[0013] In certain aspects, the present invention provides a compound defined herein or a pharmaceutically acceptable salt thereof.

[0014] In another aspect, the present invention provides a pharmaceutical composition as defined herein comprising a compound as defined herein or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

[0015] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0016] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.

[0017] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer. In certain embodiments, the cancer is a human cancer.

[0018] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in inhibiting METTL3 activity.

[0019] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an autoimmune disease.

[0020] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a neurological disease.

[0021] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an infectious disease.

[0022] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an inflammatory disease.

[0023] In another aspect, the present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a proliferative condition.

[0024] In another aspect, the present invention provides the use of a compound as defined herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of cancer. In certain embodiments, the medicament is for use in the treatment of human cancer.

[0025] In another aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of METTL3 activity.

[0026] In another aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an autoimmune disease.

[0027] In another aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a neurological disease.

[0028] In another aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an infectious disease.

[0029] In another aspect, the present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an inflammatory disease.

[0030] In another aspect, the present invention provides a method for inhibiting METTL3 activity in vitro or in vivo, comprising contacting a cell with an effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0031] In another aspect, the present invention provides a method of inhibiting cell proliferation in vitro or in vivo, comprising contacting a cell with an effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0032] In another aspect, the present invention provides a method of inhibiting metastasis in vitro or in vivo, comprising contacting a cell with an effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0033] In another aspect, the present invention provides a method for treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0034] In another aspect, the present invention provides a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0035] In another aspect, the present invention provides a method for treating an autoimmune disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0036] In another aspect, the present invention provides a method for treating a neurological disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0037] In another aspect, the present invention provides a method for treating an infectious disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0038] In another aspect, the present invention provides a method for treating an inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition defined herein.

[0039] In certain embodiments, the present invention provides a combination comprising a compound defined herein, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.

[0040] The present invention further provides methods for synthesizing the compounds defined herein or pharmaceutically acceptable salts thereof.

[0041] In another aspect, the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, obtainable by, obtained by, or directly obtained through a synthetic method as defined herein.

[0042] In another aspect, the present invention provides novel intermediates as defined herein that are suitable for use in any one of the synthetic methods set forth herein.

[0043] Preferred, appropriate and optional features of any particular embodiment of the present invention are also preferred, appropriate and optional features of any other embodiment. [Brief explanation of the drawings]

[0044] For a more detailed understanding of the present invention, and to show how the same may be carried into effect, reference will now be made, by way of example, to the following figures: [Figure 1] Schematic of the MOLM13 AML proliferation assay with measurement of m6A levels [Figure 2] m6A levels in total RNA from MOLM13 (+IFNy) on day 4 [Figure 3] MOLM13 growth inhibition Day 6 [Figure 4] MOLM13 CD14 expression inhibition Day 6 [Figure 5] Growth inhibition of MOLM14, Kasumi-1, NOMO-1 and THP.1 on day 7 (IFN-treated) [Figure 6] KCL-22 growth inhibition, day 6 (IFN-treated) DETAILED DESCRIPTION OF THE INVENTION

[0045] Detailed Description of the Invention definition Unless otherwise stated, the following terms used in the specification and claims have the meanings indicated below.

[0046] References to "treating" or "treatment" are understood to include prevention and alleviation of symptoms of an established condition. Accordingly, "treating" or "treatment" of a condition, disorder, or condition includes: (1) preventing or delaying the appearance of clinical symptoms of the condition, disorder, or condition as it develops in a person who may be affected by or susceptible to the condition, disorder, or condition but who has not yet experienced or displayed clinical or subclinical symptoms of the condition, disorder, or condition; (2) inhibiting the condition, disorder, or condition, i.e., arresting, reducing, or slowing the progression of the disease or its progression (in the case of maintenance therapy) or at least one clinical or subclinical symptom thereof; or (3) remission or attenuation of the disease, i.e., causing regression of the condition, disorder, or condition or at least one clinical or subclinical symptom thereof.

[0047] A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal being treated.

[0048] As used herein, the term "alkyl" includes both straight-chain and branched-chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight-chain version only, and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched chain only. For example, "C 1-6 "Alkyl" is C 1-4 Alkyl, C 1-3 This includes alkyl, propyl, isopropyl, and t-butyl. A similar convention applies to other radicals, e.g., "phenyl (C 1-6 alkyl)" is phenyl (C 1-4 alkyl), benzyl, 1-phenylethyl and 2-phenylethyl.

[0049] The term “(m-nC)” or “Cm-n” or “(m-nC) group” or “Cm-n” used alone or as a prefix, refers to any group having m to n carbon atoms.

[0050] As used herein, the term "alkenyl" refers to an aliphatic group containing at least one double bond, and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl," the latter of which refers to an alkenyl moiety having substituents replacing hydrogen on one or more carbons of the alkenyl group. Such substituents may be present on one or more carbons included or not included in one or more double bonds. Furthermore, such substituents include all of the substituents contemplated for the alkyl group set forth below, except where less stable. For example, substitution of alkenyl groups with one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.

[0051] As used herein, the term "alkynyl" refers to an aliphatic group containing at least one triple bond, and is intended to include both "unsubstituted alkynyl" and "substituted alkynyl," the latter of which refers to an alkynyl moiety having substituents replacing hydrogen on one or more carbons of the alkynyl group. Such substituents may be present on one or more carbons included or not included in one or more triple bonds. Furthermore, such substituents include all of the substituents contemplated for alkyl groups listed below, except where less stable. For example, substitution of alkynyl groups with one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.

[0052] An "alkylene" group is an alkyl group that is positioned between and connects two chemical groups. 1-3 "Alkylene" means a linear saturated divalent hydrocarbon radical of one to three carbon atoms or a branched saturated divalent hydrocarbon radical of three atoms, e.g., methylene, ethylene, propylene, and the like.

[0053] The term “C m-n "Cycloalkyl" means a hydrocarbon ring containing m to n carbon atoms. For example, "C 3-6 "Cycloalkyl" means a hydrocarbon ring containing 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. m-n "Cycloalkyl" also encompasses non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic carbocyclic ring systems. m-n "Cycloalkyl" includes both monovalent and divalent species. m-n A "cycloalkyl" ring contains about 3 to 12 (suitably 3 to 8, more suitably 5 to 6) ring carbon atoms. m-n Cycloalkyl" contains 7 to 17 ring carbon atoms, suitably 7 to 12 ring carbon atoms. m-n Cycloalkyl rings can be fused, spiro (eg, spiro[3,3]heptane), or bridged ring systems (eg, bicyclo[2.2.1]hept-2-ene and bicyclo[1.1.1]pentanyl).

[0054] The term "halo" or "halogeno" refers to fluoro, chloro, bromo and iodo.

[0055] The terms "heterocyclyl," "heterocyclic," or "heterocycle" refer to a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system. The term heterocyclyl includes both monovalent and divalent species. Monocyclic heterocyclic rings contain about 3 to 12 (suitably 3 to 7, most suitably 5 to 6) ring atoms with 1 to 5 (suitably 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur in the ring. Bicyclic heterocycles contain 7 to 17 ring atoms, suitably 7 to 12 ring atoms in the ring. Bicyclic heterocycles contain about 7 to about 17 ring atoms, suitably 7 to 12 ring atoms. Bicyclic heterocyclic rings can be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers and substituted cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, and dioxanyl. Nitrogen-containing heterocycles include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, and tetrahydropyrazolyl. Typical sulfur-containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepin. Other heterocycles include dihydrooxathiolyl, tetrahydrooxazolyl, tetrahydrooxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, oxidized sulfur heterocycles containing SO or SO groups are also included, examples of which include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl, such as tetrahydrothienyl 1,1-dioxide and thiomorpholinyl 1,1-dioxide.Suitable values ​​for a heterocyclyl group having one or two oxo (=O) or thioxo (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3- to 7-membered heterocyclyls containing one, two, or three heteroatoms selected from nitrogen, oxygen, or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl, or homopiperazinyl. As will be understood by those skilled in the art, any heterocycle may be bonded via any suitable atom, for example, via a carbon or nitrogen atom. However, reference to piperidino or morpholino herein refers to a piperidin-1-yl or morpholin-4-yl ring bonded via the ring nitrogen.

[0056] "Bridged ring system" means a ring system in which two rings share more than two atoms. See, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, quinuclidine, 6-azabicyclo[3.1.1]heptane, 8-azabicyclo[3.2.1]octane, bicyclo[3.2.1]octane, 7-oxabicyclo[2.2.1]hept-2-ene, and 3-oxa-8-azabicyclo[3.2.1]octane.

[0057] The term "heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic, or polycyclic ring containing one or more (e.g., 1 to 4, particularly 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur. The term heteroaryl includes both monovalent and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, and more usually 5 to 10 ring members. Heteroaryl groups can be, for example, 5- or 6-membered monocyclic rings or 9- or 10-membered bicyclic rings, e.g., fused 5- and 6-membered rings or bicyclic structures formed from two fused 6-membered rings. Each ring can contain up to about four heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, heteroaryl rings contain up to three heteroatoms, more usually up to two, e.g., one heteroatom. In certain embodiments, heteroaryl rings contain at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl ring can be basic, as in the case of an imidazole or pyridine, or non-basic, as in the case of an indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents on the ring, will be fewer than five.

[0058] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, and isoquinolyl. These include aryl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, and imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also includes partially aromatic bicyclic or polycyclic ring systems in which at least one ring is aromatic and one or more other rings are non-aromatic, saturated, or partially saturated, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of partially aromatic heteroaryl groups include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzothienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.

[0059] Examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl groups.

[0060] Examples of 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.

[0061] The bicyclic heteroaryl group can be, for example, a group selected from: a benzene ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; a pyrrole ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; a pyrazine ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing one or two ring heteroatoms; a thiophene ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a furan ring fused to a five- or six-membered ring containing one, two, or three ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2, or 3 ring heteroatoms; and A cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2, or 3 ring heteroatoms.

[0062] Particular examples of bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring include, but are not limited to, benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adenyl, guaninyl), indazolyl, benzodioxolyl, and pyrazolopyridinyl groups.

[0063] Specific examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.

[0064] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes both monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. In certain embodiments, the aryl is phenyl.

[0065] The term "optionally substituted" refers to groups, structures, or molecules that are substituted or unsubstituted.

[0066] When any substituent is selected from "one or more" groups, this definition should be understood to include all substituents selected from one of the specified groups or substituents selected from two or more of the specified groups.

[0067] The phrase "compounds of the invention" means compounds disclosed generally and specifically herein.

[0068] Compounds of the Invention In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony, X is [ka] [In the formula, R 1a , R 1b , R 1c , R 1d , R 1e and R 1f are independently hydrogen, cyano, halo, or a group of the formula: -L 1a -L 1b -Q1 {In the formula, L 1a does not exist or C 1-3 Alkylene and C 3-5 cycloalkylene, wherein said C 1-3 Alkylene and C 3-5 The cycloalkylene is optionally selected from aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl, C 1-3 Alkyl, Cyano, C 1-3 Alkoxy, halo, hydroxy, C 1-3 Haloalkoxy, -OC 3-4 and optionally substituted with one or more substituents selected from cycloalkyl, NH2, or oxo; 3-6 Cycloalkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl or C 1-3 The alkyl may optionally be cyano, hydroxy, C 1-3 Alkoxy, Halo, C 1-3 Haloalkoxy, -OC 3-4and optionally further substituted with one or more substituents selected from cycloalkyl or NH; 3-6 The cycloalkyl may optionally be further substituted with halo, cyano, or hydroxy; or C 1-3 The alkylene may optionally be spiro-fused with a 3- to 5-membered cycloalkyl or heterocyclic ring or spirocyclic ring system, each of which may optionally be C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 optionally substituted with one or more substituents selected from haloalkoxy; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-3 alkyl, wherein said C 1-3 The alkyl may optionally be cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NH2, C 3-6 cycloalkyl or 3- to 6-membered heterocyclyl, wherein 3-6 The cycloalkyl or 3- to 6-membered heterocyclyl may optionally be substituted with halo, hydroxy, C 1-2 Alkoxy or C 1-2 optionally further substituted with haloalkoxy; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 including cycloalkyl), C 2-3 Alkenyl, C 2-3alkynyl, aryl, heterocyclyl (monocyclic or bicyclic heterocyclic ring system, spirocyclic heterocyclic ring system or bridged heterocyclic ring system) or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, oxo, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , -S(O) 0-2 R t R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u wherein z is 1, 2 or 3, and wherein 1-4 The alkyl may optionally be cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 haloalkoxy, -O-C3 cycloalkyl, wherein -O-C3 cycloalkyl is optionally further substituted with halo, cyano, or hydroxy; t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ), or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), aryl or heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , -S(O) 0-2 R t1 R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with a group is selected from the group R 1a’ is selected from hydrogen, halo, and methyl; R 2a , R 2b and R 2c is hydrogen, halo or of the formula: -L 2a -L 2b -Q2 {In the formula, L 2a does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 2b is absent or O, S, SO, SO2, N(R n ), C(O), C(O)O, OC(O), C(O)N(R n ), N(R n )C(O),N(R n )C(O)N(R o ), S(O)2N(R n ) or N(R n )SO2, wherein said R n and R o are each independently hydrogen or C 1-2 alkyl; Q2 is hydrogen, cyano, C 1-6 Alkyl, C 3-6cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, C 1-4 Alkyl, NR p R q , OR p , C(O)R p , C(O)OR p ,OC(O)R p , C(O)N(R p )R q , N(R r )C(O)R p , S(O) y R p (y is 0, 1, or 2), SO2N(R p )R q , N(R r )SO2R p or (CH2) z NR p R q (z is 1, 2 or 3), wherein R p and R q are each independently hydrogen or C 1-4 alkyl} selected from the group Selected from; Y is [ka] [ka] (In the formula, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 are independently hydrogen (including deuterium), C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl, or C 3-4 The cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is hydrogen or halo; However, when n=1 or n=2, R 3a1 , R 3b1 , R 3i1 , R 3l1 , R 3o1 , R 3r1 , R 3a2 , R 3b2 , R 3i2 , R 3l2 , R 3o2 and R 3s1 cannot be halo and the carbon atom to which they are attached is attached to an oxygen or nitrogen atom; or R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2, R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 , R 3q1 and R 3q2 , or R 3r1 and R 3r2 or R 3s1 and R 3s2 together with the carbon atoms to which they are attached, form a spiro-fused C which may be optionally substituted with one or more substituents selected from halo, methyl, amino, cyano and hydroxy. 3-4 may be bonded to form a cycloalkyl is selected from Z is [ka] (In the formula, R4, R7, R 4a and R 7a is independently selected from hydrogen, halo, cyano, and methyl; R5, R 5a , R 5b and R 5c is independently selected from hydrogen, halo, cyano, and methyl; R6, R8, R 6a and R 8a is independently selected from hydrogen, halo, cyano, and methyl; R9, R 9a , R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 alkyl; or R9 and R10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R 11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; wherein either of the fused 5- or 6-membered saturated or unsaturated ring systems is optionally 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ia R 1ja or -S(O) 0-2 R 1ia R 1ja wherein R 1ia and R 1ja is H or C 1-2 is alkyl; R Z1 and R Z1a is hydrogen, C 1-4 Alkyl, cyano, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 3-6 Cycloalkyl and -OC 3-6 cycloalkyl, wherein said C 3-6 Cycloalkyl and -OC 3-6 The cycloalkyl may be optionally substituted with one or more halo, methyl, or methoxy; R Z2 and R Z2a is hydrogen, C 1-4 Alkyl, cyano, halo, NH2 and C 1-4 selected from alkoxy; R Z3a is hydrogen, C 1-4 Alkyl, cyano, halo, NH2 and C 1-4 selected from alkoxy; A1 is CR 12 and N; A2 is CR 13 and N; A3 is CR14 and N; A4 is CR 15 and N; A5 is CR 16 and N; A6 is CR 17 and N; A7 is CR 18 and N; A8 is CR 19 R 20 and N.R. 21 Selected from; A9 is CR 22 R 23 and N.R. 24 Selected from; A 10 is CR 25 R 26 and N.R. 27 Selected from; A 11 is CR 28 R 29 and N.R. 30 Selected from; R 12 and R 14 are independently hydrogen, halo, cyano and C 1-4 alkyl; R 13 is selected from hydrogen, halo, cyano, methoxy and methyl; R 15 is selected from hydrogen, halo, cyano, methoxy and methyl; R 16 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-4 Cycloalkyl, 3-4 membered heterocyclyl and C 3-4 cycloalkoxy; R 17 is hydrogen, hydroxy, halo, cyano, C 1-5 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon bond), -(OCH2CH2) m -NR q R r , -(OCH2CH2) m -OCH3 (m is an integer from 1 to 6), NR q R r , -C(O)-NR q R r , -C(O)OR q Selected from; Here, R q and R r are each independently hydrogen, C 1-5 Alkyl, C 3-6 cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl, wherein the C 1-5 Alkyl, C 3-6 Cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl may optionally be C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 is alkyl; or R q and R r together with the nitrogen atom to which they are attached, may be C 1-2 -Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2joined together to form a 3- to 6-membered heterocyclic ring optionally substituted with one or more substituents selected from haloalkoxy; where any C 1-5 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, or -O-heterocyclyl (carbon bond) is optionally represented by C 1-2 Alkyl, Cyano, C 1-2 -haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 is alkyl; R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, 5- or 6-membered heteroaryl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-4 Cycloalkyl, 3-4 membered heterocyclyl and C 3-4 - selected from cycloalkoxy; R 19 , R 20 , R 25 and R 26 are hydrogen, halo, cyano and C 1-4 alkyl; R 22 and R 23 is selected from hydrogen, halo, cyano and methyl; R 28 and R 29is selected from hydrogen, methoxy and methyl; R 21 , R 24 , R 27 and R 30 is hydrogen; n is 0, 1, or 2) selected from Although it is a compound of 2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole; 2-((6-chloro-1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-3-yl)-1,3,4-oxadiazole; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-5-carboxamide or a pharmaceutically acceptable salt thereof, wherein

[0069] In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony, X is [ka] [In the formula, R 1a , R 1b , R 1c , R 1d , R 1e and R 1f are independently hydrogen, cyano, halo, or a group of the formula: -L 1a -L 1b -Q1 {In the formula, L 1a is absent or optionally aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl, C 1-2 C, optionally substituted with one or more substituents selected from alkyl, cyano, halo, hydroxy, or oxo 1-3Alkylene or C 3-4 cycloalkylene; wherein any aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl or C 1-2 The alkyl may optionally be further substituted with one or more substituents selected from halo, cyano, or hydroxy; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl, wherein said C 1-2 The alkyl may optionally be C 3-6 cycloalkyl or 3-6 membered heterocyclyl, which in turn may be optionally substituted with halo, hydroxy, C 1-2 Alkoxy or C 1-2 optionally further substituted with haloalkoxy; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 -Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, oxo, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u, N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u (wherein z is 1, 2 or 3), and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 cycloalkyl, heterocyclyl, phenyl, or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NRt1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 (wherein z is 1, 2, or 3), wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be replaced by is selected from the group R 1a’ is selected from hydrogen, halo, and methyl; R 2a , R 2b and R 2c is hydrogen, halo or of the formula: -L 2a -L 2b -Q2 (In the formula, L 2a does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 2b is absent or O, S, SO, SO2, N(R n ), C(O), C(O)O, OC(O), C(O)N(R n ), N(R n)C(O),N(R n )C(O)N(R o ), S(O)2N(R n ) or N(R n )SO2, wherein said R n and R o are each independently hydrogen or C 1-2 alkyl; Q2 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, C 1-4 Alkyl, NR p R q , OR p , C(O)R p , C(O)OR p ,OC(O)R p , C(O)N(R p )R q , N(R r )C(O)R p , S(O) y R p (wherein y is 0, 1 or 2), SO2N(R p )R q , N(R r )SO2R p or (CH2) z NR p R q where z is 1, 2, or 3, and wherein R p and R q are each independently hydrogen or C 1-4 alkyl) selected from the group Selected from; Y is [ka] [ka] (In the formula, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 ,R 3q1 , R 3r1 and R 3s1 are independently hydrogen (including deuterium), C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl or C 3-4 The cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is hydrogen or halo; However, when n=1 or n=2, R 3a1 , R 3b1 , R 3i1 , R 3l1 , R 3o1 , R 3r1 , R 3a2 , R 3b2 , R 3i2 , R 3l2 , R 3o2 and R3s2 cannot be halo and the carbon atom to which they are attached is attached to an oxygen or nitrogen atom; or R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 , R 3q1 and R 3q2 , R 3r1 and R 3r2 or R 3s1 and R 3s2 together with the carbon atoms to which they are attached, form a spiro-fused C which may be optionally substituted with one or more substituents selected from halo, methyl, amino, cyano and hydroxy. 3-4 may be bonded to form a cycloalkyl is selected from Z is [ka] (In the formula, R4, R7, R 4a and R 7a is independently selected from hydrogen, halo, cyano, and methyl; R5, R 5a , R 5b and R 5cis independently selected from hydrogen, halo, cyano, and methyl; R6, R8, R 6a and R 8a is independently selected from hydrogen, halo, cyano, and methyl; R9, R 9a , R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 alkyl; or R9 and R 10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R 11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; wherein either of the fused 5- or 6-membered saturated or unsaturated ring systems is optionally 1-2 -Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ia R 1ja or -S(O) 0-2 R 1ia R 1ja and R 1ia and R 1ja is H or C 1-2 is alkyl; R Z1 and R Z1a is hydrogen, C 1-4 Alkyl, cyano, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 3-6 Cycloalkyl and -OC 3-6 cycloalkyl, wherein said C 3-6 Cycloalkyl and -OC 3-6 The cycloalkyl may be optionally substituted with one or more halo, methyl, or methoxy; R Z2 and R Z2a is hydrogen, C 1-4Alkyl, cyano, halo, NH2 and C 1-4 selected from alkoxy; R Z3a is hydrogen, C 1-4 Alkyl, cyano, halo, NH2 and C 1-4 selected from alkoxy; A1 is CR 12 and N; A2 is CR 13 and N; A3 is CR 14 and N; A4 is CR 15 and N; A5 is CR 16 and N; A6 is CR 17 and N; A7 is CR 18 and N; A8 is CR 19 R 20 and N.R. 21 Selected from; A9 is CR 22 R 23 and N.R. 24 Selected from; A 10 is CR 25 R 26 and N.R. 27 Selected from; A 11 is CR 28 R 29 and N.R. 30 Selected from; R 12 and R 14 are independently hydrogen, halo, cyano and C 1-4 alkyl; R 13 is selected from hydrogen, halo, cyano, methoxy and methyl; R 15 is selected from hydrogen, halo, cyano, methoxy and methyl; R 16 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-4 Cycloalkyl, 3-4 membered heterocyclyl and C 3-4 cycloalkoxy; R 17 is hydrogen, hydroxy, halo, cyano, C 1-5 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon bond), -(OCH2CH2) m -NR q R r , -(OCH2CH2) m -OCH3 (m is an integer from 1 to 6), NR q R r , -C(O)-NR q R r , -C(O)OR q Selected from; Here, R q and R r are each independently hydrogen, C 1-5 Alkyl, C 3-6 cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl, wherein the C 1-5 Alkyl, C 3-6 Cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl may optionally be C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C1-2 is alkyl; or R q and R r together with the nitrogen atom to which they are attached, may be C 1-2 -Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 joined together to form a 3- to 6-membered heterocyclic ring optionally substituted with one or more substituents selected from haloalkoxy; where any C 1-5 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, or -O-heterocyclyl (carbon bond) is optionally represented by C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 is alkyl; R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, 5- or 6-membered heteroaryl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-4 Cycloalkyl, 3-4 membered heterocyclyl and C 3-4 - selected from cycloalkoxy; R 19 , R 20 , R 25and R 26 are hydrogen, halo, cyano and C 1-4 alkyl; R 22 and R 23 is selected from hydrogen, halo, cyano and methyl; R 28 and R 29 is selected from hydrogen, methoxy and methyl; R 21 , R 24 , R 27 and R 30 is hydrogen; n is 0, 1, or 2) selected from or a pharmaceutically acceptable salt thereof.

[0070] In one embodiment, the present invention provides a compound of formula (I): [ka] [During the ceremony, X is [ka] [In the formula, R 1a , R 1b , R 1c , R 1d , R 1e and R 1f are independently hydrogen, cyano, halo, or a group of the formula: -L 1a -L 1b -Q1 {In the formula, L 1a does not exist or in some cases C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(Rr ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ), or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 cycloalkyl, heterocyclyl, phenyl, or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with a group Selected from; R 1a’ is selected from hydrogen and methyl; R 2a , R 2b and R 2c is hydrogen or the formula: -L 2a -L 2b -Q2 (In the formula, L 2a does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 2b are O, S, SO, SO2, N(R n ), C(O), C(O)O, OC(O), C(O)N(R n ), N(R n )C(O),N(R n )C(O)N(R o ), S(O)2N(R n ) or N(R n )SO2, wherein said R n and R o are each independently hydrogen or C 1-2 alkyl; Q2 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, C 1-4 Alkyl, NR p R q , OR p , C(O)R p , C(O)ORp ,OC(O)R p , C(O)N(R p )R q , N(R r )C(O)R p , S(O) y R p (wherein y is 0, 1 or 2), SO2N(R p )R q , N(R r )SO2R p or (CH2) z NR p R q where z is 1, 2, or 3, and wherein R p and R q are each independently hydrogen or C 1-4 alkyl) selected from the group Selected from; Y is [ka] (In the formula, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 are independently hydrogen, C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl, or C 3-4 The cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 and R 3o2 is hydrogen; or R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 or R 3o1 and R 3o2 is a spiro-fused C bonded to a ring, which is optionally substituted with one or more substituents selected from halo, amino, cyano and hydroxy; 3-4 (which can form a cycloalkyl) Selected from; Z is [ka] (In the formula, R4, R7, R 4a and R 7a is independently selected from hydrogen and methyl; R5, R 5a and R 5b is independently selected from hydrogen and halo; R6, R8, R 6aand R 8a is independently selected from hydrogen, halo, and methyl; R9, R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 alkyl; or R9 and R 10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R 11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; A1 is CR 12 and N; A2 is CR 13 and N; A3 is CR 14 and N; A4 is CR 15 and N; A5 is CR 16 and N; A6 is CR 17 and N; A7 is CR 18 and N; A8 is CR 19 R 20 and N.R. 21 Selected from N; A9 is CR 22 R 23 and N.R. 24 Selected from N; A 10 is CR 25 R 26 and N.R. 27 Selected from N; A 11 is CR 28 R 29 and N.R. 30 Selected from N; R 12 and R 14 are independently hydrogen, halo, cyano and C 1-4 alkyl; R 13is selected from hydrogen, halo, cyano and methyl; R 15 is selected from hydrogen, methoxy and methyl; R 16 are hydrogen, halo, cyano and C 1-4 alkyl; R 17 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl; R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl; R 19 , R 20 , R 25 and R 26 are hydrogen, halo, cyano and C 1-4 alkyl; R 22 and R 23 is selected from hydrogen, halo, cyano and methyl; R 28 and R 29 is selected from hydrogen, methoxy and methyl; R 21 , R 24 , R 27 and R 30 is selected from hydrogen; n is 0, 1, or 2) selected from or a pharmaceutically acceptable salt thereof.

[0071] In one embodiment, the present invention provides a compound of formula (I) shown below: [ka] [During the ceremony, X is [ka] [In the formula, R 1a , R 1b , R 1c , R 1d , R 1e and R 1f are independently hydrogen, cyano, halo, or a group of the formula: -L 1a -L 1b -Q1 {In the formula, L 1a does not exist or in some cases C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 Cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t, C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d does not exist or is C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is phenyl or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, Halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 1-4and optionally substituted with one or more substituents selected from alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl, or sulfamoyl. may be substituted with a group is selected from the group R 1a’ is selected from hydrogen and methyl; R 2a , R 2b and R 2c is hydrogen or the formula: -L 2a -L 2b -Q2 (In the formula, L 2a does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 2b are O, S, SO, SO2, N(R n ), C(O), C(O)O, OC(O), C(O)N(R n ), N(R n )C(O),N(R n )C(O)N(R o ), S(O)2N(R n ) or N(R n )SO2, wherein said R n and R o are each independently hydrogen or C 1-2 alkyl; Q2 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, C 1-4 Alkyl, NR p R q , OR p , C(O)R p , C(O)OR p ,OC(O)R p , C(O)N(R p )R q, N(R r )C(O)R p , S(O) y R p (wherein y is 0, 1 or 2), SO2N(R p )R q , N(R r )SO2R p or (CH2) z NR p R q where z is 1, 2, or 3, and wherein R p and R q are each independently hydrogen or C 1-4 alkyl) selected from the group Selected from; Y is [ka] (In the formula, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 are independently hydrogen, C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl or C 3-4 The cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 and R 3o2 is hydrogen; or R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 and R 3o1 and R 3o2 is a spiro-fused C bonded to a ring, which is optionally substituted with one or more substituents selected from halo, amino, cyano and hydroxy; 3-4 (which can form a cycloalkyl) Selected from; Z is [ka] (In the formula, R4, R7, R 4a and R 7a is independently selected from hydrogen and methyl; R5, R 5a and R 5b is independently selected from hydrogen and halo; R6, R8, R 6a and R 8a is independently selected from hydrogen, halo, and methyl; R9, R10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 alkyl; or R9 and R 10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R 11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; A1 is CR 12 and N; A2 is CR 13 and N; A3 is CR 14 and N; A4 is CR 15 and N; A5 is CR 16 and N; A6 is CR 17 and N; A7 is CR 18 and N; A8 is CR 19 R 20 and N.R. 21 Selected from N; A9 is CR 22 R 23 and N.R. 24 Selected from N; A 10 is CR 25 R 26 and N.R. 27 Selected from N; A 11 is CR 28 R 29 and N.R. 30 Selected from N; R 12 and R 14 are independently hydrogen, halo, cyano and C 1-4 alkyl; R 13 is selected from hydrogen, halo, cyano and methyl; R 15is selected from hydrogen, methoxy and methyl; R 16 are hydrogen, halo, cyano and C 1-4 alkyl; R 17 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl; R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 alkynyl and 5- or 6-membered heteroaryl; R 19 , R 20 , R 25 and R 26 are hydrogen, halo, cyano and C 1-4 alkyl; R 22 and R 23 are hydrogen, halo, cyano and methyl; R 28 and R 29 are hydrogen, methoxy and methyl; R 21 , R 24 , R 27 and R 30 is hydrogen; n is 0, 1, or 2) selected from or a pharmaceutically acceptable salt thereof.

[0072] Particular compounds of the present invention include, for example, compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein, unless otherwise specified, X, Y, Z, R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1a’ , R 2a , R 2b , R 2c , R 3a1 , R 3a2 , R3b1 , R 3b2 , R 3c1 , R 3c2 , R 3d1 , R 3d2 , R 3e1 , R 3e2 , R 3f1 , R 3f2 , R 3g1 , R 3g2 , R 3h1 , R 3h2 , R 3i1 , R 3i2 , R 3j1 , R 3j2 , R 3k1 , R 3k2 , R 3l1 , R 3l2 , R 3m1 , R 3m2 , R 3n1 , R 3n2 , R 3o1 , R 3o2 ,n,R4,R 4a , R5, R 5a , R 5b , R 5c , R6, R 6a , R7, R 7a , R8, R 8a , R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , A1, A2, A3, A4, A5, A6, A7, A8, A9, A 10 and A 11 and any associated substituents each have any of the meanings defined above or below in paragraphs (1) to (111b).

[0073] (1)R 1a and R 1b , R 1c and R 1d , R 1e and R 1f One of them is hydrogen, halo, C 1-6 Alkyl, C 2-3 Alkenyl or -OC 1-6 alkyl, The other is hydrogen, cyano, halo or the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or in some cases C 1-2 optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo; 1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t, C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d does not exist or is C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is phenyl or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, Halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C1-4 Alkoxy, C 1-4 and optionally substituted with one or more substituents selected from alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl, or sulfamoyl. may be substituted with] selected from the group

[0074] (1a)R 1a and R 1b , R 1c and R 1d , R 1e and R 1f One of them is hydrogen, halo, C 1-6 Alkyl, C 2-3 Alkenyl or -OC 1-6 alkyl, The other is hydrogen, cyano, halo or the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or, in some cases, C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said Rv and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] selected from the group

[0075] (1b)R 1a and R 1b , R 1c and R 1d , R 1e and R 1f One of them is hydrogen, halo, C 1-6 Alkyl, C 2-3 Alkenyl or -OC 1-6 alkyl, The other is hydrogen, cyano, halo or the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl, C 1-2 C, optionally substituted with one or more substituents selected from alkyl, cyano, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 cycloalkylene, where any aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl or C 1-2 The alkyl may optionally be further substituted with one or more substituents selected from halo, cyano, or hydroxy; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl, wherein said C 1-2 Alkyl is optionally substituted with halo, hydroxy, C 1-2 Alkoxy or C 1-2 C which may be further substituted with haloalkoxy3-6 optionally further substituted with cycloalkyl or 3- to 6-membered heterocyclyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, oxo, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1dis absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ), or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] selected from the group

[0076] (2)R 1a , R 1c and R 1e is hydrogen, halo, C 1-6 Alkyl, C 2-3 Alkenyl or -OC 1-6 alkyl R 1b , R 1d and R 1f is hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or in some cases C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-3 Alkenyl, C 2-3alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d does not exist or is C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2 and R v and R ware each independently hydrogen or C 1-2 alkyl; Z1 is phenyl or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, Halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 1-4 and optionally substituted with one or more substituents selected from alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl, or sulfamoyl. may be substituted with] selected from the group

[0077] (3)R 1a , R 1c and R 1e is hydrogen, halo, C 1-4 Alkyl, C 2-3 Alkenyl and -OC 1-4 selected from alkyl;

[0078] (4)R 1a , R 1c and R 1e is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, propyl, butyl, ethenyl, -O-methyl, -O-ethyl, -O-propyl and -O-butyl;

[0079] (5)R 1a , R 1c and R 1e is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, -O-methyl, ethenyl and -O-ethyl;

[0080] (6)R 1a , R 1c and R 1e is selected from hydrogen, fluoro, bromo, methyl, ethenyl and -O-methyl;

[0081] (6a)R 1b , R 1d and R 1fis hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or in some cases C 1-2 substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo; 1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(Rt )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] selected from the group

[0082] (6b)R 1b , R 1d and R 1f is hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl, C 1-2 C, optionally substituted with one or more substituents selected from alkyl, cyano, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4cycloalkylene, where any aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl or C 1-2 The alkyl may optionally be further substituted with one or more substituents selected from halo, cyano, or hydroxy; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl, wherein said C 1-2 The alkyl may optionally be C 3-6 cycloalkyl or 3- to 6-membered heterocyclyl, wherein 3-6 The cycloalkyl or 3- to 6-membered heterocyclyl may optionally be substituted with halo, hydroxy, C 1-2 Alkoxy or C 1-2 optionally further substituted with haloalkoxy; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, oxo, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t)R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, where R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from C 1-4 Alkyl, C 3-6Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] selected from the group

[0083] (7)R 1b , R 1d and R 1f is hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or in some cases C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d does not exist or is C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, wherein said R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is phenyl or 5- to 6-membered heteroaryl; wherein said Z1 is optionally C 1-4 Alkyl, Halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 1-4 and optionally substituted with one or more substituents selected from alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl, or sulfamoyl. may be substituted with] selected from the group

[0084] (7a)R 1b , R 1d and R 1f is hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist, or in some cases C 1-2 C, optionally substituted with one or more substituents selected from alkyl, halo, hydroxy, or oxo1-3 Alkylene or C 3-4 is cycloalkylene; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(R r ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R u where z is 1, 2, or 3, and wherein R t and Ru are each independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, where R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1 , N(R t1 )C(O)R u1 , S(O)y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] selected from the group

[0085] (7b)R 1b , R 1d and R 1f is hydrogen, cyano, halo or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl, C 1-2 C, optionally substituted with one or more substituents selected from alkyl, cyano, halo, hydroxy, or oxo 1-3 Alkylene or C 3-4 cycloalkylene, where any aryl, aryl-(1-2C)alkyl, heteroaryl, aryl-(1-2C)alkyl or C 1-2 The alkyl may be optionally substituted with one or more substituents selected from halo, cyano, or hydroxy; L 1b is absent or O, S, SO, SO2, N(R r ), C(O), C(O)O, OC(O), C(O)N(Rr ), N(R r )C(O),N(R r )C(O)N(R s ), S(O)2N(R r ) or N(R r )SO2, wherein said R r and R s are each independently hydrogen or C 1-2 alkyl, wherein said C 1-2 The alkyl may optionally be C 3-6 cycloalkyl or 3- to 6-membered heterocyclyl, wherein 3-6 The cycloalkyl or 3- to 6-membered heterocyclyl may optionally be substituted with halo, hydroxy, C 1-2 Alkoxy or C 1-2 optionally further substituted with haloalkoxy; Q1 is hydrogen, cyano, C 1-6 Alkyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), C 2-3 Alkenyl, C 2-3 alkynyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally C 1-4 Alkyl, halo, trifluoromethyl, trifluoromethoxy, amino, oxo, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t , C(O)R t , C(O)OR t ,OC(O)R t , C(O)N(R t )R u , N(R t )C(O)R u , S(O) y R t (wherein y is 0, 1 or 2), SO2N(R t )R u , N(R t )SO2R u or (CH2) z NR t R uwhere z is 1, 2, or 3, and wherein R t and R u are each independently hydrogen or C 1-4 alkyl; Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist or C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 1d is absent or C(O), O, C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R v )C(O)N(R w ), S(O)2N(R v ) or N(R v )SO2, where R v and R w are each independently hydrogen or C 1-2 alkyl; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl), heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems), phenyl or 5-6 membered heteroaryl; wherein said Z1 is optionally selected from the group consisting of C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, cyano, hydroxyl, NR t1 R u1 , OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 , C(O)N(R t1 )R u1, N(R t1 )C(O)R u1 , S(O) y R t1 (wherein y is 0, 1 or 2), SO2N(R t1 )R u1 , N(R t1 )SO2R u1 or (CH2) z NR t1 R u1 where z is 1, 2, or 3, and wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z is C 3-8 When Z is cycloalkyl or heterocyclyl, Z is optionally C 3-6 may be spiro-fused with a cycloalkyl or heterocyclyl ring; may be substituted with] selected from the group

[0086] (8)R 1b , R 1d and R 1f is hydrogen, halo, cyano, or has the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally substituted with one or more hydroxy 1-3 is alkylene; L 1b does not exist or R r is hydrogen N(R r ) and; Q1 is C 1-6 Alkyl, C 2-3 Alkenyl, C 3-8 Cycloalkyl (e.g., C 3-6 cycloalkyl), aryl, heterocyclyl, or heteroaryl; wherein Q1 is optionally halo, carboxy, trifluoromethyl, NR t R u , ORt wherein R t and R u are independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is phenyl or 5-6 membered heteroaryl; wherein said Z1 optionally contains one or more C 1-4 may be substituted with alkyl may be substituted with] Derived from the group of;

[0087] (8a)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally substituted with one or more hydroxy 1-3 is alkylene; L 1b does not exist or R r is hydrogen or C 1-4 N(R r ) and; Q1 is C 1-6 Alkyl, C 2-3 Alkenyl, C 3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally halo, carboxy, trifluoromethyl, NR t R u , OR t wherein R t and R uare independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is phenyl, 5- to 6-membered heteroaryl, C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl) or heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems); wherein said Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 wherein R t1 and R u1 are each independently hydrogen or C 1-4 alkyl; Z1 is optionally selected from C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with] Derived from the group of;

[0088] (8b)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is C 1-3 is alkylene; L 1b is R r is hydrogen or C 1-4N(R r ) and; Q1 is C 1-6 alkyl, heterocyclyl, or heteroaryl; wherein said Q1 is optionally halo, carboxy, trifluoromethyl, NR t R u , OR t wherein R t and R u are independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl) or heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems); wherein said Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, OR t1 , C(O)R t1 , C(O)OR t1 ,OC(O)R t1 wherein R t1 is hydrogen or C 1-4 alkyl; Z1 is optionally selected from C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with a group Derived from the group of;

[0089] (8c)R 1b , R 1d and R 1f is selected from hydrogen or a group of formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is C 1-3 is alkylene; L 1b is R r is hydrogen or C 1-4 N(R r ) and; Q1 is C 1-6 alkyl; wherein Q1 is optionally halo, carboxy, trifluoromethyl, NR t R u , OR t wherein R t and R u are independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 cycloalkyl); wherein Z1 is optionally C 1-4 Alkyl, C 3-6 Cycloalkyl, heterocyclyl, halo, C 1-4 Haloalkyl, OR t1 or C(O)OR t1 wherein R t1 is hydrogen or C 1-4 alkyl; Z1 is optionally selected from C 3-6 may be spiro-fused to a cycloalkyl or heterocyclyl ring may be substituted with a group Derived from the group of;

[0090] (8d)R1b , R 1d and R 1f is selected from hydrogen or a group of formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is C 1-3 is alkylene; L 1b is R r is hydrogen N(R r ) and; Q1 is C 1-6 alkyl; wherein Q1 is optionally halo, carboxy, trifluoromethyl, NR t R u , OR t wherein R t and R u are independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 [During the ceremony, L 1c does not exist; L 1d does not exist; Z1 is C 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 wherein Z1 is optionally C 1-4 Alkyl or halo, C 1-4 Haloalkyl, OR t1 or C(O)OR t1 wherein R t1 is hydrogen or C 1-4 alkyl) may be substituted with a group Derived from the group of;

[0091] (8e)R 1b , R 1d and R1f is selected from hydrogen or a group of formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is C 1-3 is alkylene; L 1b is R r is hydrogen N(R r ) and; Q1 is an expression greater than or equal to 1: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 may be C 1-4 C, which may be substituted with one or more groups selected from alkyl or halo 3-8 Cycloalkyl (spirocyclic, carbocyclic and bridged C 3-8 (including cycloalkyl) C, which may be substituted with a group 1-6 alkyl] Derived from the group of;

[0092] (9)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano or a group of formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or C 1-3 is alkylene; L 1b does not exist or R r is hydrogen N(R r ) and; Q1C 1-6 alkyl, where The Q1 has the formula: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is phenyl is substituted with a group Derived from the group of;

[0093] (9a)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a is absent or optionally substituted with one or more hydroxy 1-3 is alkylene; L 1b does not exist; Q1 is a 5- or 6-membered aryl, a 5- or 6-membered heteroaryl, a 5- or 6-membered heterocyclyl, or a 7-, 8-, or 9-membered bridged heterocycle, wherein said Q1 is optionally halo, NR t R u , OR t wherein R t and R u are independently hydrogen or C 1-4 alkyl; or Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is a 5- to 6-membered heteroaryl; wherein said Z1 optionally comprises one or more C 1-4 may be substituted with alkyl may be substituted with a group Derived from the group of;

[0094] (10)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist or C 1-3 alkylene, optionally substituted by one or more hydroxy; L 1b does not exist or R r is hydrogen N(R r ) and; Q1 is a 5- or 6-membered aryl, a 5- or 6-membered heteroaryl, or a 5- or 6-membered heterocyclyl, wherein said Q1 is optionally halo, NR t R u , OR t wherein R t and R u are independently hydrogen or C 1-4 alkyl; Q1 is optionally one or more of the following expressions: -L 1c -L 1d -Z1 (In the formula, L 1c does not exist; L 1d does not exist; Z1 is a 5- to 6-membered heteroaryl; wherein said Z1 optionally comprises one or more C 1-4 may be substituted with alkyl may be substituted with a group Derived from the group of;

[0095] (11)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L1a is absent or optionally substituted with one hydroxyl; 1-3 is alkylene; L 1b does not exist or R r is hydrogen N(R r ) and; Q1 is phenyl, pyrazolyl, piperazinyl or pyridinyl, wherein said Q1 is optionally substituted with one or more substituents selected from chloro and methoxy. Derived from the group of;

[0096] (12)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist; L 1b does not exist or R r is hydrogen N(R r ) and; Q1 is optionally substituted with 5- to 6-membered heteroaryl; 1-6 alkyl; wherein said 5- to 6-membered heteroaryl is optionally selected from C 1-4 Alkyl, Halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 1-4 and optionally substituted with one or more substituents selected from alkylamino, amino, cyano, hydroxyl, carboxy, carbamoyl, or sulfamoyl. Derived from the group of;

[0097] (13)R 1b , R 1d and R 1f is selected from hydrogen, halo, cyano, or a group of the formula: -L 1a -L 1b -Q1 [During the ceremony, L 1a does not exist; L 1b does not exist or R r is hydrogen N(R r ) and; Q1 is optionally substituted with piperazinyl, imidazolyl or pyridyl; 1-6 alkyl, wherein said imidazolyl is optionally C 1-4 may be substituted with alkyl. Derived from the group of;

[0098] (14)R 1b , R 1d and R 1f is hydrogen; halo; cyano; hydroxy; C optionally substituted with OH, NH2, 5- to 6-membered aryl, carboxy, and / or 5- to 6-membered heterocyclyl 1-6 Alkyl; C 1-6 Alkyloxy;C 2-3 Alkenyl; C 3-6 Cycloalkyl;-C 1-3 Alkylene-NH-C 1-6 Alkyl (wherein C 1-6 alkyl optionally substituted with OH, trifluoromethyl, carboxy, or phenyl); -NH-heteroaryl, where heteroaryl is a 5- or 6-membered heteroaryl; 5- or 6-membered heteroaryl; 5- or 6-membered heterocyclic; optionally -OC 1-4 5- or 6-membered aryl optionally substituted with alkyl or halo; and -NH-C 1-6 Alkyl (wherein C 1-6 The alkyl may be optionally substituted with a 5- or 6-membered heteroaryl, and the 5- or 6-membered heteroaryl may optionally be C 1-4 and optionally substituted with alkyl;

[0099] (14a)R 1b , R 1d and R 1f are independently hydrogen, halo, cyano, hydroxy, C 1-4Alkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy or selected from the formula: -(CR 1c’ R 1d’ ) p -NR 1e’ R 1f’ [During the ceremony, p is an integer selected from 1 or 2; R 1c’ and R 1d’ is independent, (i) hydrogen (including deuterium); (ii) cyano, hydroxy, C 1-3 Alkoxy, Halo, C 1-3 Haloalkoxy, -OC 3-4 C optionally substituted with one or more substituents selected from cycloalkyl or NH 1-3 alkyl, wherein said -OC 3-6 cycloalkyl optionally substituted with halo, cyano or hydroxy; C 1-3 alkyl, or (iii)R 1c’ and R 1d’ are joined together with the carbon atom to which they are attached to form a 3- to 5-membered cycloalkyl or heterocyclic ring or spirocyclic ring system, wherein each of said 3- to 5-membered cycloalkyl or heterocyclic ring or spirocyclic ring system optionally includes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 may be substituted with one or more substituents selected from haloalkoxy is selected from R 1e’ teeth (i) Hydrogen (including deuterium); (ii) optionally cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 C optionally substituted with one or more substituents selected from haloalkoxy and NH 1-3 Alkyl Selected from; R 1f’ is the expression: -(CR 1g R 1h ) q -T1 (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R 1g and R 1h is independent, a) hydrogen (including deuterium); or b) optionally cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 C optionally substituted with one or more substituents selected from haloalkoxy, -O-C3 cycloalkyl 1-3 alkyl, wherein said -O-C3 cycloalkyl is optionally substituted with halo, cyano or hydroxy; C 1-3 Alkyl Selected from; T1 is C 3-8 Cycloalkyl, aryl, heterocyclyl, heteroaryl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl, or bridged heterocyclic ring systems, each of which is optionally selected from C 1-2 -Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy) is a group having the formula: or R 1e’ and R 1f’ together with the nitrogen atom to which they are attached, and sometimes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1i R 1j or -S(O) 0-2 R 1i R 1jand R are linked to form a monocyclic or bicyclic heterocyclic ring, which may be substituted with one or more substituents selected from 1i and R 1j is H or C 1-2 alkyl, and / or R 1e and R 1f The monocyclic or bicyclic heterocyclic ring formed by 3-6 may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may optionally be C 1-2 Alkyl, cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1i R 1j or -S(O) 0-2 R 1i R 1j wherein R 1i and R 1j is H or C 1-2 alkyl] It is based on.

[0100] (14b)R 1d and R 1f are independently hydrogen, halo, cyano, hydroxy, C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 1b is the expression: -(CR 1c’ R 1d’ ) p -NR 1e’ R 1f’ ; [During the ceremony, p is an integer selected from 1 or 2; R 1c’ and R 1d’ is independent, (i) hydrogen (including deuterium) or (ii) optionally cyano, hydroxy, C 1-2 Alkoxy, Halo, C 1-2C optionally substituted with one or more substituents selected from haloalkoxy, -O-C3 cycloalkyl 1-3 Alkyl Selected from; R 1e’ is hydrogen (including deuterium) or C 1-2 is alkyl; R 1f’ is the expression: -(CR 1g R 1h ) q -T1 (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R 1g and R 1h is independent, a) hydrogen (including deuterium); or b) optionally cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 C optionally substituted with one or more substituents selected from haloalkoxy 1-2 Alkyl Selected from; T1 is C 3-8 Cycloalkyl, aryl, heterocyclyl, heteroaryl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl or a bridged heterocyclic ring system, each of which is optionally selected from C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy) is a group having the formula: or R 1e’ and R 1f’ together with the nitrogen atom to which they are attached, and sometimes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2haloalkoxy; and / or R 1e and R 1f The monocyclic or bicyclic heterocyclic ring formed by 3-6 may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may optionally be C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy] It comes from the group

[0101] (14c)R 1d and R 1f are independently hydrogen, halo, cyano, hydroxy, C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; and R 1b is the expression: -(CR 1c’ R 1d’ ) p -NR 1e’ R 1f’ ; [During the ceremony, p is an integer selected from 1 or 2; R 1c’ and R 1d’ are independently hydrogen (including deuterium) or C 1-2 alkyl; R 1e’ is hydrogen (including deuterium) or C 1-2 alkyl; R 1f’ is the expression: -(CR 1g R 1h ) q -T1 (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R 1g and R 1hare independently hydrogen (including deuterium) or C 1-2 alkyl; T1 is C 3-4 Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl, or bridged heterocyclic ring systems, each of which is optionally selected from C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy) is a group having the formula: or R 1e’ and R 1f’ together with the nitrogen atom to which they are attached, and sometimes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy; and / or R 1e and R 1f The monocyclic or bicyclic heterocyclic ring formed by 3-6 may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may optionally be C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy] is the basis of;

[0102] (14d)R 1d and R 1f are independently selected from hydrogen, halo, cyano, hydroxy, methyl, and methoxy; R 1b is the expression: -(CR 1c’ R 1d’ ) p -NR 1e’ R1f’ ; [During the ceremony, p is 1; R 1c’ and R 1d’ are independently hydrogen (including deuterium) or C 1-2 alkyl; R 1e’ is hydrogen (including deuterium) or C 1-2 alkyl; R 1f’ is the expression: -(CR 1g R 1h ) q -T1 (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R 1g and R 1h are independently hydrogen (including deuterium) or C 1-2 alkyl; T1 is C 3-4 Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl or a bridged heterocyclic ring system, each of which is optionally selected from C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy) is a group having the formula: or R 1e’ and R 1f’ together with the nitrogen atom to which they are attached, and sometimes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy; and / or R 1e and R 1f The monocyclic or bicyclic heterocyclic ring formed by3-6 These may then be spiro-fused with a cycloalkyl or heterocyclic ring; 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy] It is based on.

[0103] (14e)R 1d and R 1f are independently selected from hydrogen, halo, cyano, hydroxy, methyl, and methoxy; R 1b is the expression: -(CR 1c’ R 1d’ ) p -NR 1e’ R 1f’ ; [During the ceremony, p is 1; R 1c’ and R 1d’ are independently hydrogen (including deuterium) or C 1-2 alkyl; R 1e’ is hydrogen (including deuterium) or C 1-2 alkyl; R 1f’ is the expression: -(CR 1g R 1h ) q -T1 (In the formula, q is 1; R 1g and R 1h are independently hydrogen (including deuterium) or C 1-2 alkyl; T1 is C 3-4 Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl or a bridged heterocyclic ring system, each of which is optionally selected from C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C1-2 Alkoxy, halo or C 1-2 haloalkoxy) is a group having the formula It is based on.

[0104] (14f)R 1d and R 1f are independently selected from hydrogen, halo, cyano, hydroxy, methyl, and methoxy; R 1b is the expression: -(CR 1c’ R 1d’ ) p -NR 1e’ R 1f’ ; [During the ceremony, p is 1; R 1c’ and R 1d’ are independently hydrogen (including deuterium) or C 1-2 alkyl; R 1e’ and R 1f’ together with the nitrogen atom to which they are attached, and sometimes C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy, and / or R 1e and R 1f The monocyclic or bicyclic heterocyclic ring formed by 3-6 may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may optionally be C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy] It is based on.

[0105] (14g)R 1d and R 1fare independently selected from hydrogen, halo, cyano, hydroxy, methyl, and methoxy; R 1b is an expression [ka] [Wherein T1 is C 3-4 Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C 3-8 cycloalkyl or bridged heterocyclic ring systems, each of which is optionally C 1-2 -Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo or C 1-2 haloalkoxy] It is based on.

[0106] (15)R 1b , R 1d and R 1f are hydrogen; bromo; chloro; fluoro; cyano; methyl; hydroxy; methoxy; [ka] [ka] Selected from;

[0107] (15a)R 1d and R 1f is selected from hydrogen; bromo; chloro; fluoro; cyano; methyl; methoxy; R 1b teeth [ka] [ka] [ka] is selected from.

[0108] (15b)R 1b , R 1d and R 1f are hydrogen; bromo; chloro; fluoro; cyano; methyl; methoxy; [ka] [ka] [ka] [ka] [ka] [ka] Selected from;

[0109] (15c)R 1b , R 1d and R 1f are hydrogen; bromo; chloro; fluoro; cyano; methyl; methoxy, [ka] [ka] [ka] is selected from.

[0110] (15d)R 1b , R 1d and R 1f teeth [ka] [ka] [ka] [ka] [ka] [ka] [ka] is selected from.

[0111] (15e)R 1b , R 1d and R 1f teeth [ka] is selected from.

[0112] (15f)R 1b , R 1d and R 1f teeth [ka] is selected from.

[0113] (15g)R 1b , R 1d and R 1f teeth [ka] is.

[0114] (16)R 1a’ is selected from hydrogen, halo and methyl;

[0115] (16a)R 1a’ are hydrogen and methyl;

[0116] (17)R 1a’ is hydrogen;

[0117] (18)R2a , R 2b and R 2c is hydrogen, halo or of the formula: -L 2a -L 2b -Q2 [During the ceremony, L 2a does not exist or in some cases C 1-2 C optionally substituted with alkyl or oxo 1-3 is alkylene; L 2b is absent or O, S, SO, SO2, N(R n ), C(O), C(O)O, OC(O), C(O)N(R n ), N(R n )C(O),N(R n )C(O)N(R o ), S(O)2N(R n ) or N(R n )SO2, wherein said R n and R o are each independently hydrogen or C 1-2 alkyl; Q2 is hydrogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, C 1-4 Alkyl, NR p R q , OR p , C(O)R p , C(O)OR p ,OC(O)R p , C(O)N(R p )R q , N(R r )C(O)R p , S(O) y R p (wherein y is 0, 1 or 2), SO2N(R p )R q , N(R r )SO2R p or (CH2)z NR p R q where z is 1, 2, or 3, and wherein R p and R q are each independently hydrogen or C 1-4 alkyl] selected from the group

[0118] (19)R 2a , R 2b and R 2c is hydrogen;

[0119] (20) X is [ka] [In the formula, R 1a , R 1b , R 1a’ and R 2a is as defined herein. is;

[0120] (21) X is [ka] [In the formula, R 1c , R 1d and R 2b is as defined herein. is;

[0121] (22) X is [ka] [In the formula, R 1e , R 1f and R 2c is as defined herein. is;

[0122] (23) X is [ka] [ka] [ka] [ka] Selected from;

[0123] (24) X is [ka] is;

[0124] (24a) X is [ka] is;

[0125] (25)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 are independently hydrogen, C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo, wherein said C 1-6 Alkyl or C 3-4 Cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2, R 3l2 , R 3m2 , R 3n2 and R 3o2 is hydrogen;

[0126] (25a)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 are independently hydrogen, C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl or C 3-4 Cycloalkyl may be optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 and R 3q2 is hydrogen;

[0127] (25b)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 are independently hydrogen, C 1-6 Alkyl, C 3-4 cycloalkyl, hydroxy, and halo; 1-6 Alkyl or C 3-4 Cycloalkyl is optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy; R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is hydrogen;

[0128] (26)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 are independently hydrogen and C 1-6 alkyl; wherein said C 1-6 The alkyl may be optionally substituted with one or more hydroxy substituents;

[0129] (26a)R3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 are independently hydrogen and C 1-6 alkyl; wherein said C 1-6 The alkyl may be optionally substituted with one or more hydroxy substituents;

[0130] (26b)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 are independently hydrogen and C 1-6 alkyl; wherein said C 1-6 The alkyl may be optionally substituted with one or more hydroxy substituents;

[0131] (27)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R3n1 and R 3o1 is independently selected from hydrogen and methyl; wherein said methyl is optionally substituted with one or more hydroxy substituents;

[0132] (27a)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 is independently selected from hydrogen and methyl; wherein said methyl is optionally substituted with one or more hydroxy substituents;

[0133] (27b)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 is independently selected from hydrogen and methyl; wherein said methyl is optionally substituted with one or more hydroxy substituents;

[0134] (28)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 is independently selected from hydrogen and methyl; wherein said methyl may be substituted with a hydroxy substituent;

[0135] (28a)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 is independently selected from hydrogen and methyl; wherein said methyl may be substituted with a hydroxy substituent;

[0136] (28b)R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 is independently selected from hydrogen and methyl; wherein said methyl may be substituted with a hydroxy substituent;

[0137] (29)R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 and R 3o2 is hydrogen;

[0138] (29a)R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 and R 3q2 is hydrogen;

[0139] (29b)R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is hydrogen;

[0140] (30)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 or R 3o1 and R 3o2 is hydrogen;

[0141] (30a)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 , R 3q1 and R 3q2 is hydrogen.

[0142] (30b)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 , R 3q1 and R 3q2 , R 3r1 and R 3r2 and R 3s1 and R 3s2 is hydrogen.

[0143] (31)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2is bonded to a spiro-fused C which is optionally substituted with one or more substituents selected from halo, amino, cyano and hydroxy 3-4 Can form cycloalkyl;

[0144] (31a)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R 3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 , R 3q1 and R 3q2 is bonded to a spiro-fused C which is optionally substituted with one or more substituents selected from halo, amino, cyano and hydroxy 3-4 Can form cycloalkyl;

[0145] (31b)R 3a1 and R 3a2 , R 3b1 and R 3b2 , R 3c1 and R 3c2 , R 3d1 and R 3d2 , R 3e1 and R 3e2 , R 3f1 and R 3f2 , R 3g1 and R 3g2 , R 3h1 and R3h2 , R 3i1 and R 3i2 , R 3j1 and R 3j2 , R 3k1 and R 3k2 , R 3l1 and R 3l2 , R 3m1 and R 3m2 , R 3n1 and R 3n2 , R 3o1 and R 3o2 , R 3p1 and R 3p2 and R 3q1 and R 3q2 is bonded to a spiro-fused C which is optionally substituted with one or more substituents selected from halo, amino, cyano and hydroxy 3-4 Can form cycloalkyl;

[0146] (32) n is 0, 1, or 2;

[0147] (33) n is 1;

[0148] (34) Y is [ka] [In the formula, R 3a1 , R 3a2 and n is as defined herein. is;

[0149] (34a) Y is [ka] wherein n is 1 and R 3a1 , R 3a2 is as defined herein. is;

[0150] (35) Y is [ka] wherein n is as defined herein;

[0151] (36) Y is [ka] [In the formula, R 3b1 , R 3b2 and n is as defined herein. is;

[0152] (37) Y is [ka] [In the formula, R 3c1 , R 3c2 and n is as defined herein. is;

[0153] (38) Y is [ka] [In the formula, R 3d1 , R 3d2 and n is as defined herein. is;

[0154] (39) Y is [ka] [In the formula, R 3e1 , R 3e2 and n is as defined herein. is;

[0155] (40) Y is [ka] is;

[0156] (41) Y is [ka] [In the formula, R 3f1 , R 3f2and n is as defined herein. is;

[0157] (42) Y is [ka] [In the formula, R 3g1 , R 3g2 and n is as defined herein. is;

[0158] (43) Y is [ka] [In the formula, R 3h1 , R 3h2 and n is as defined herein.

[0159] (44) Y is [ka] [In the formula, R 3i1 , R 3i2 and n is as defined herein. is;

[0160] (45) Y is [ka] [In the formula, R 3j1 , R 3j2 and n is as defined herein. is;

[0161] (46) Y is [ka] [In the formula, R 3k1 , R 3k2 and n is as defined herein. is;

[0162] (47) Y is [ka] [In the formula, R 3l1 , R 3l2 and n is as defined herein. is;

[0163] (48) Y is [ka] [In the formula, R 3m1 , R 3m2 and n is as defined herein. is;

[0164] (49) Y is [ka] [In the formula, R 3n1 , R 3n2 and n is as defined herein. is;

[0165] (50) Y is [ka] [In the formula, R 3o1 , R 3o2 and n is as defined herein. is;

[0166] (50a)Y is [ka] [In the formula, R 3p1 , R 3p2 and n is as defined herein. is;

[0167] (50b) Y is [ka] [In the formula, R3q1 , R 3q2 and n is as defined herein. is;

[0168] (50c)Y is [ka] [In the formula, R 3r1 , R 3r2 and n is as defined herein. is; (50d)Y is [ka] [In the formula, R 3s1 , R 3s2 and n is as defined herein. is;

[0169] (51) Y is [ka] Selected from;

[0170] (52) Y is [ka] is;

[0171] (52a) Y is [ka] Selected from;

[0172] (53) R4 is selected from hydrogen and methyl;

[0173] (54) R4 is hydrogen;

[0174] (55) R5 is selected from hydrogen and halo;

[0175] (56) R5 is hydrogen;

[0176] (57) R6 is selected from hydrogen, halo, and methyl;

[0177] (58) R6 is hydrogen;

[0178] (59) R4, R5, and R6 are hydrogen;

[0179] (60) A1 is CR 12 and N, wherein R 12 are hydrogen, halo, cyano and C 1-4 selected from alkyl;

[0180] (61) A1 is CH;

[0181] (62) A2 is CR 13 and N, wherein R 13 is selected from hydrogen, halo, cyano and methyl;

[0182] (63) Suitably, A2 is CH;

[0183] (64) A1 is CH and A2 is CH;

[0184] (65) R7 is selected from hydrogen, halo, and methyl;

[0185] (65a) R7 is selected from hydrogen and methyl;

[0186] (66) R7 is hydrogen;

[0187] (67) R8 is selected from hydrogen, halo, and methyl;

[0188] (68) R8 is hydrogen;

[0189] (69) R7 and R8 are hydrogen;

[0190] (70) A3 is CR14 and N, wherein R 14 are hydrogen, halo, cyano and C 1-4 selected from alkyl;

[0191] (71) A3 is CR 14 where R 14 is selected from hydrogen and chloro;

[0192] (72) A3 is CH;

[0193] (73) A4 is CR 15 and N, wherein R 15 is selected from hydrogen, methoxy and methyl;

[0194] (74) A4 is CH;

[0195] (75) A3 is CH and A4 is CH;

[0196] (76) A5 is CR 16 and N, wherein R 16 are hydrogen, halo, cyano and C 1-4 selected from alkyl;

[0197] (76a)A5 is CR 16 and N, wherein R 16 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy and C 3-4 selected from cycloalkoxy;

[0198] (76b)A5 is CR 16 and N, wherein R 16 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl and C 1-4 selected from haloalkoxy;

[0199] (76c)A5 is CR 16 and N, wherein R 16 are hydrogen, halo, cyano and C 1-4 selected from alkoxy;

[0200] (77) A5 is CH;

[0201] (78) A6 is CR 17 and N, wherein R 17 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl;

[0202] (78a)A6 is CR 17 and N, wherein R 17 is hydrogen, halo, cyano, C 1-5 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon bond), -(OCH2CH2) m -OCH3 (wherein m is an integer of 1 to 6), NR q R r is selected from R q and R r are each independently hydrogen, C 1-5 Alkyl, C 3-6 cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl, wherein the C 1-5 Alkyl, C 3-6 Cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl may optionally be C 1-2 Alkyl, Cyano, C 1-2Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 is alkyl; or R q and R r together with the nitrogen atoms to which they are attached, form C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 linked to form a 3- to 6-membered heterocyclic ring optionally substituted with one or more substituents selected from haloalkoxy; where any C 1-5 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, or -O-heterocyclyl (carbon bond) is optionally represented by C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 It is alkyl.

[0203] (78b)A6 is CR 17 and N, wherein R 17 is hydrogen, halo, cyano, C1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon bond), -(OCH2CH2) m -OCH3 (wherein m is an integer of 1 to 6), NR q R r wherein R is selected from q and R r are each independently hydrogen, C 1-2 alkyl or R q and R r are linked together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclic ring; where any C 1- Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered or heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, or -O-heterocyclyl (carbon bond) is optionally represented by C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ea R 1fa or -S(O) 0-2 R 1ea R 1fa wherein R 1ea and R 1fa is H or C 1-2 It is alkyl.

[0204] (78c)A6 is CR 17 and N, wherein R 17 is hydrogen, halo, cyano, C1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon bond), -(OCH2CH2) m -OCH3 (wherein m is 1, 2, or 3), NR q R r wherein R is selected from q and R r are each independently hydrogen, C 1-4 alkyl; or R q and R r , together with the nitrogen atom to which they are attached, are bonded to form a 3- to 6-membered heterocyclic ring; where any C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, phenyl, 5- or 6-membered heteroaryl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, heterocyclyl, or -O-heterocyclyl (carbon bond) is optionally represented by C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo and C 1-2 It may be further substituted with one or more substituents selected from haloalkoxy.

[0205] (78d)A6 is CR 17 and N, wherein R 17 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, -OC3-4 Cycloalkyl, heterocyclyl, -(OCH2CH2) m -OCH3 (wherein m is 1, 2 or 3), NR q R r , where R q and R r are each independently hydrogen or C 1-2 alkyl; where any C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, -OC 3-4 Cycloalkyl and heterocyclyl systems are optionally C 1-2 Alkyl, C 1-2 Haloalkyl, cyano, hydroxy, C 1-2 Alkoxy, halo and C 1-2 It may be further substituted with one or more substituents selected from haloalkoxy.

[0206] (79) A6 is CR 17 where R 17 is hydrogen, halo, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl;

[0207] (79a)A6 is CR 17 where R 17 is hydrogen, halo, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl;

[0208] (79b)A6 is CR 17 where R 17 is hydrogen, halo, C 1-4 Alkoxy or C 1-4 selected from haloalkoxy;

[0209] (80) A6 is CR 17 where R 17is selected from hydrogen, bromo, ethynyl and pyrazolyl;

[0210] (80a)A6 is CR 17 where R 17 is selected from hydrogen, methoxy, bromo, ethynyl and pyrazolyl;

[0211] (81) A5 is CH and A6 is CR 17 where R 17 is hydrogen, halo, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl;

[0212] (82) R9, R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 selected from alkyl;

[0213] (82a)R9, R 9a , R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 selected from alkyl;

[0214] (82c)R9, R 10 and R 11 are independently hydrogen, NH2, halo, cyano and C 1-6 alkyl; and R 9a is hydrogen;

[0215] (83)R9 and R 10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R 11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system;

[0216] (83a) R9 and R 10 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R 10 and R11 may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; wherein said fused 5- or 6-membered saturated or unsaturated ring system optionally includes C 1-2 Alkyl, Cyano, C 1-2 Haloalkyl, hydroxy, C 1-2 Alkoxy, Halo, C 1-2 Haloalkoxy, NR 1ia R 1ja or -S(O) 0-2 R 1ia R 1ja wherein R 1ia and R 1ja is H or C 1-2 is alkyl;

[0217] (84) A7 is CR 18 and N, wherein R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 selected from alkynyl and 5- or 6-membered heteroaryl;

[0218] (85a)A7 is CR 18 and N, wherein R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy and C 3-4 - selected from cycloalkoxy;

[0219] (85b)A7 is CR 18 and N, wherein R 18 is hydrogen, halo, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl and C 1-4 selected from haloalkoxy;

[0220] (85c)A7 is CR 18and N, wherein R 18 are hydrogen, halo, cyano and C 1-4 selected from alkoxy;

[0221] (85) A7 is CH;

[0222] (86)R 4a is selected from hydrogen, halo and methyl;

[0223] (86a)R 4a is selected from hydrogen and methyl;

[0224] (87)R 4a is hydrogen;

[0225] (88)R 5a is selected from hydrogen and halo;

[0226] (89)R 5a is hydrogen;

[0227] (90)R 6a is selected from hydrogen, halo and methyl;

[0228] (91)R 6a is hydrogen;

[0229] (92)R 4a , R 5a and R 6a is hydrogen;

[0230] (93) A8 is CR 19 R 20 and N.R. 21 wherein R is selected from 19 and R 20 are hydrogen, halo, cyano and C 1-4 alkyl, and R 21 is hydrogen;

[0231] (94) A9 is CR 22 R 23 and N.R. 24wherein R is selected from 22 and R 23 is selected from hydrogen, halo, cyano, and methyl; R 24 is hydrogen;

[0232] (95)R 5b is selected from hydrogen and halo;

[0233] (96)R 5b is hydrogen;

[0234] (96a)R 5c is selected from hydrogen and halo;

[0235] (96b)R 5c is hydrogen;

[0236] (97)R 7a is selected from hydrogen, halo and methyl;

[0237] (97a)R 7a is selected from hydrogen and methyl;

[0238] (98)R 7a is hydrogen;

[0239] (99)R 8a is selected from hydrogen, halo and methyl;

[0240] (100)R 8a is hydrogen;

[0241] (101)R 5b , R 7a and R 8a is hydrogen;

[0242] (102)A 10 is CR 25 R 26 and N.R. 27 wherein R is selected from 25 and R 26 are hydrogen, halo, cyano and C 1-4alkyl, and R 27 is selected from hydrogen;

[0243] (103)A 11 is CR 28 R 29 and N.R. 30 wherein R is selected from 28 and R 29 is selected from hydrogen, methoxy and methyl, and R 30 is hydrogen;

[0244] (104a)R Z1 and R Z1a is hydrogen, C 1-4 Alkyl, cyano, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Alkoxy, C 3-6 Cycloalkyl and -OC 3-6 cycloalkyl, wherein said C 3-6 Cycloalkyl and -OC 3-6 The cycloalkyl may be optionally substituted with one or more halo, methyl, or methoxy;

[0245] (104b)R Z1 and R Z1a is hydrogen, C 1-2 Alkyl, cyano, halo, C 1-2 Haloalkyl, C 1-2 Haloalkoxy, C 1-2 selected from alkoxy;

[0246] (104c)R Z1 and R Z1a is hydrogen, C 1-2 selected from alkyl, cyano and halo;

[0247] (104d)R Z1 and R Z1a is hydrogen;

[0248] (104e)R Z2 and R Z2a is hydrogen, C1-4 Alkyl, cyano, halo or C 1-4 selected from alkoxy;

[0249] (104f)R Z2 and R Z2a is selected from hydrogen, cyano, or halo;

[0250] (104g)R Z2 and R Z2a is hydrogen;

[0251] (104h)R Z3a is hydrogen, C 1-4 Alkyl, cyano, halo or C 1-4 selected from alkoxy;

[0252] (104i)R Z3a is selected from hydrogen, cyano, or halo;

[0253] (104j)R Z3a is hydrogen;

[0254] (104k)Z is [ka] [In the formula, R4, R 4a , R5, R 5a , R 5b , R 5c , R6, R 6a , R7, R 7a , R8, R 8a , R Z1 , R Z1a , R Z2 , R Z2a , R Z3a , A1, A2, A3, A4, A5, A6, A7, A8, A9, A 10 and A 11 is as defined herein. is selected from.

[0255] (104)Z is [ka] wherein R, R, R, A, and A are as defined herein. is;

[0256] (105)Z is [ka] wherein R7, R8, A3 and A4 are as defined herein. is;

[0257] (105a)Z is [ka] [In the formula, R 5c , R7, R8, A3 and A4 are as defined herein. is;

[0258] (106)Z is [ka] wherein A5 and A6 are as defined herein. is;

[0259] (106a)Z is [ka] [In the formula, R Z1 , R Z2 , A5 and A6 are as defined herein. is;

[0260] (107)Z is [ka] [In the formula, R9, R 10 and R 11 is as defined herein. is;

[0261] (107a)Z is [ka] [In the formula, R9, R 9a , R 10 and R 11 is as defined herein. is;

[0262] (108)Z is [ka] wherein A7 is as defined herein. is;

[0263] (108a)Z is [ka] [In the formula, R Z1a , R Z2a , R Z3a and A7 is as defined herein. is;

[0264] (109)Z is [ka] [In the formula, R 4a , R 5a , R 6a , A8 and A9 are as defined herein. is;

[0265] (110)Z is [ka] [In the formula, R 5b , R 7a , R 8a , A 10 and A 11 is as defined herein. is;

[0266] (111)Z is [ka] is selected from.

[0267] (111a)Z is [ka] [ka] is selected from.

[0268] (111b)Z is [ka] is selected from.

[0269] Suitably, a heteroaryl or heterocyclyl group as defined herein is a monocyclic heteroaryl or heterocyclyl group containing 1, 2 or 3 heteroatoms selected from N, O or S.

[0270] Suitably, the heteroaryl is a 5- or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from N, O or S.

[0271] Suitably, the heterocyclyl group is a 4-, 5- or 6-membered heterocyclyl ring containing 1, 2 or 3 heteroatoms selected from N, O or S. Most suitably, the heterocyclyl group is a 5- or 6-membered ring containing 1, 2 or 3 heteroatoms selected from N, O or S [e.g., morpholinyl (e.g., 4-morpholinyl), oxetane, methyloxetane (e.g., 3-methyloxetane), pyrrolidinone (e.g., pyrrolidin-2-one)].

[0272] Suitably the aryl group is phenyl.

[0273] Suitably, X is as defined in any one of paragraphs (20) to (24) above. Most suitably, X is as defined in paragraph (20).

[0274] Suitably, X is as defined in any one of paragraphs (20) to (24a) above. Most suitably, X is as defined in paragraph (20) or (24a).

[0275] Appropriately, R 1a , R 1c and R 1e is as defined in any one of paragraphs (1) to (6) above. Most suitably, R 1a , R 1c and R 1e is as defined in paragraph (6).

[0276] Appropriately, R 1b , R 1d and R 1f is as defined in any one of paragraphs (1), (2) and (7) through (15) above. Most suitably, R 1b , R 1d and R 1f is as defined in paragraph (15).

[0277] Appropriately, R 1b , R 1d and R 1f is as defined in any one of paragraphs (1), (2) and (6a) through (15a) above. Most suitably, R 1b , R 1d and R 1f is as defined in paragraph (15a).

[0278] Appropriately, R 1b , R 1d and R 1f is as defined in any one of paragraphs (14a) to (15c) above. Suitably, R 1b , R 1d and R 1fis as defined in any one of paragraphs (14d) to (15c). 1b , R 1d and R 1f is as defined in paragraph (15c).

[0279] Appropriately, R 1b , R 1d and R 1f is as defined in any one of paragraphs (14a) to (15g) above. Suitably, R 1b , R 1d and R 1f is as defined in any one of paragraphs (14a) to (14g). 1b , R 1d and R 1f is as defined in any one of paragraphs (15d) to (15g). Most appropriately, R 1b , R 1d and R 1f is as defined in paragraph (15g).

[0280] Appropriately, R 1a’ is as defined in paragraphs (16) and (17) above. Most appropriately, R 1a’ is as defined in paragraph (17) above.

[0281] Appropriately, R 2a , R 2b and R 2c is as defined in any one of paragraphs (18) and (19) above. Most suitably, R 2a , R 2b and R 2c is as defined in paragraph (19) above.

[0282] Suitably, Y is as defined in any one of paragraphs (34) to (52) above. Suitably, Y is as defined in paragraphs (34), (34a), (36), (39), (40), (43) and (50c). Suitably, Y is as defined in paragraph (34a) or (43) above. Most suitably, Y is as defined in paragraph (52a) above.

[0283] Suitably, n is as defined in any one of paragraphs (32) and (33) above. Most suitably, n is as defined in paragraph (33).

[0284] Appropriately, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above. Most suitably, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 and R 3o1 is as defined in paragraph (28).

[0285] Appropriately, R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 and R 3o2 is as defined in any one of paragraphs (25), (29), (30) and (31) above. Most suitably, R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 and R 3o2 is as defined in paragraph (29).

[0286] Appropriately, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 and R 3q1 is as defined in any one of paragraphs (25) to (28a) and (30) to (31a) above. Most suitably, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R3p1 and R 3q1 is as defined in paragraph (28a).

[0287] Appropriately, R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 and R 3q2 is as defined in any one of paragraphs (25), (25a), (29), (29a), (30), (30a), (31) and (31a) above. Most suitably, R 3a2 , R 3b2 , R 3c2 , R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 and R 3q2 is as defined in paragraph (29a).

[0288] Appropriately, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1, R 3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 is as defined in any one of paragraphs (25) to (28b) and (30a) to (31b) above. Most suitably, R 3a1 , R 3b1 , R 3c1 , R 3d1 , R 3e1 , R 3f1 , R 3g1 , R 3h1 , R 3i1 , R 3j1 , R 3k1 , R 3l1 , R 3m1 , R 3n1 , R 3o1 , R 3p1 , R 3q1 , R 3r1 and R 3s1 is as defined in paragraph (28b).

[0289] Appropriately, R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R 3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is as defined in any one of paragraphs (25), (25a), (25b), (29), (29a), (29b), (30), (30a), (30b), (31), (31a) and (31b) above. Most suitably, R 3a2 , R 3b2 , R 3c2 , R 3d2 , R 3e2 , R 3f2 , R 3g2 , R 3h2 , R3i2 , R 3j2 , R 3k2 , R 3l2 , R 3m2 , R 3n2 , R 3o2 , R 3p2 , R 3q2 , R 3r2 and R 3s2 is as defined in paragraph (29b).

[0290] Suitably, Z is as defined in any one of paragraphs (104k) and (104) to (111b) above. Suitably, Z is as defined in any one of paragraphs (104) to (111a) above. Suitably, Z is as defined in any one of paragraphs (104) to (111) above. Suitably, Z is as defined in any one of paragraphs (104) to (106a) above. Suitably, Z is as defined in paragraphs (104), (105a) and (106a). Most suitably, Z is as defined in any one of paragraphs (104) to (106). Most suitably, Z is as defined in paragraph (111b) above.

[0291] Suitably, R4 is as defined in any one of paragraphs (53), (54) and (59) above. Most suitably, R4 is as defined in paragraph (54).

[0292] Suitably, R5 is as defined in any one of paragraphs (55), (56) and (59) above. Most suitably, R5 is as defined in paragraph (56).

[0293] Suitably, R6 is as defined in any one of paragraphs (57), (58) and (59) above. Most suitably, R6 is as defined in paragraph (58).

[0294] Suitably, A1 is as defined in any one of paragraphs (60), (61) and (64) above. Most suitably, A1 is as defined in paragraph (61).

[0295] Suitably, A2 is as defined in any one of paragraphs (62), (63) and (64) above. Most suitably, A1 is as defined in paragraph (63).

[0296] Suitably, R7 is as defined in any one of paragraphs (65), (66) and (69) above. Most suitably, R7 is as defined in paragraph (66).

[0297] Suitably, R8 is as defined in any one of paragraphs (67), (68) and (69) above. Most suitably, R8 is as defined in paragraph (68).

[0298] Suitably, A3 is as defined in any one of paragraphs (70), (71), (72) and (75) above. Most suitably, A3 is as defined in paragraph (71).

[0299] Suitably, A4 is as defined in any one of paragraphs (73), (74) and (75) above. Most suitably, A4 is as defined in paragraph (74).

[0300] Suitably, A5 is as defined in any one of paragraphs (76), (76a), (76b), (76c), (77) and (81) above. Suitably, A5 is as defined in any one of paragraphs (76), (77) and (81) above. Most suitably, A5 is as defined in paragraph (77).

[0301] Suitably, A6 is as defined in any one of paragraphs (78) to (81) above. Suitably, A6 is as defined in paragraph (79). Suitably, A6 is as defined in any one of paragraphs (78a), (78b), (78c), (79a) and (79b). Most suitably, A6 is as defined in paragraph (79b).

[0302] Appropriately, R9, R10 and R 11 is as defined in any one of paragraphs (82) to (83a). 10 and R 11 is as defined in paragraphs (82) and (83).

[0303] Suitably, A7 is as defined in any one of paragraphs (84) to (85c) above. Suitably, A7 is as defined in any one of paragraphs (84) to (85) above.

[0304] Appropriately, R 4a is as defined in any one of paragraphs (86), (86a), (87) and (92) above. Most suitably, R 4a is as defined in paragraph (87).

[0305] Appropriately, R 5a is as defined in any one of paragraphs (88), (89) and (92) above. Most suitably, R 5a is as defined in paragraph (89).

[0306] Appropriately, R 6a is as defined in paragraphs (90) to (92) above. Most appropriately, R 6a is as defined in paragraph (91).

[0307] Suitably, A8 is as defined in any one of paragraphs (93) above.

[0308] Suitably, A9 is as defined in any one of paragraphs (94) above.

[0309] Appropriately, R 5b is as defined in any one of paragraphs (95) and (96) above. Most suitably, R 5b is as defined in paragraph (96).

[0310] Appropriately, R7a is as defined in any one of paragraphs (97), (97a) and (98) above. Most suitably, R 7a is as defined in paragraph (98).

[0311] Appropriately, R 8a is as defined in any one of paragraphs (99) and (100) above. Most suitably, R 8a is as defined in paragraph (100).

[0312] Appropriately, A 10 is as defined in any one of paragraphs (102) above.

[0313] Appropriately, A 11 is as defined in any one of paragraphs (103) above.

[0314] Appropriately, R Z1 and R Z1a is as defined in any one of paragraphs (104a) to (104d) above. Most suitably, R Z1 and R Z1a is as defined in paragraph (104d).

[0315] Appropriately, R Z2 and R Z2a is as defined in any one of paragraphs (104e) to (104g) above. Most suitably, R Z2 and R Z2a is as defined in paragraph (104g).

[0316] Appropriately, R Z3a is as defined in any one of paragraphs (104h) to (104j) above. Most suitably, R Z3a is as defined in paragraph (104j).

[0317] In a particular group of compounds of the present invention, Y is as defined in paragraph (34), i.e., the compound has structural formula (II) (a subdefinition of formula (1)) as shown below: [ka] [In the formula, X, R 3a1 , R 3a2 , n and Z each have any one of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0318] In an embodiment of the compound of formula (II): X is as defined in any one of paragraphs (20) to (24) above, suitably X is as defined in paragraph (24a); R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) and (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104) to (111b) above. Suitably, Z is as defined in any one of paragraphs (104) to (111) above.

[0319] In an embodiment of the compound of formula (II): X is as defined in paragraph (20) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0320] In a particular group of compounds of formula (II): X is as defined in paragraph (20), (21) or (22) above; R 1b , R1d and R 1f are each as defined in any one of paragraphs (8a) through (8e) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0321] In a particular group of compounds of formula (II): X is as defined in paragraph (20) above, and R 1b is as defined in any one of paragraphs (14a) to (14g) above; suitably, R 1b is as defined in any one of paragraphs (14a) to (15g) above. Suitably, R 1b is as defined in any one of paragraphs (15d) to (15g). Most appropriately, R 1b is as defined in paragraph (15g); R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0322] In a particular group of compounds of formula (II): X is as defined in paragraph (20) above, and R 1b is as defined in any one of paragraphs (8a) to (8e); R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0323] In a particular group of compounds of the present invention, Y is as defined in paragraph (36), i.e., the compound has structural formula (III) shown below (a subdefinition of formula (1)): [ka] [In the formula, X, R 3b1 , R 3b2 , n and Z each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0324] In an embodiment of the compound of formula (III): X is as defined in any one of paragraphs (20) to (24); R 3b1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) and (31) above; R 3b2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104) to (111) above.

[0325] In an embodiment of the compound of formula (III): X is as defined in paragraph (20) above; R 3b1 is as defined in paragraph (28) above; R 3b2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0326] In a particular group of compounds of formula (III): X is as defined in paragraph (20), (21) or (22) above; R 1b , R 1d and R 1f are each as defined in any one of paragraphs (8a) through (8e) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0327] In a particular group of compounds of formula (III): X is as defined in paragraph (20) above, and R 1b is as defined in any one of paragraphs (8a) to (8e) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0328] In a particular group of compounds of the present invention, X is as defined in paragraph (20), i.e., the compound has structural formula (IV) (a subdefinition of formula (I)) as shown below: [ka] [In the formula, R 1a , R 1b , R 1a’ , R 2a , Y and Z each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0329] In an embodiment of the compound of formula (IV): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (1), (2), and (7) through (15a) above; R 1a’ is as defined in any one of paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; Y is as defined in any one of paragraphs (34) to (52); Z is as defined in any one of paragraphs (104) to (111) above.

[0330] In an embodiment of the compound of formula (IV): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (14a) to (14g) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; Y is as defined in any one of paragraphs (34) to (52); Z is as defined in any one of paragraphs (104) to (111) above.

[0331] In an embodiment of the compound of formula (IV): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (15) or (15a) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; Y is as defined in paragraphs (34), (36), (39) and (40) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0332] In a particular group of compounds of formula (IV): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b As defined in any one of paragraphs (8a) through (8e) or (15a) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; Y is as defined in any one of paragraphs (34) to (52) above; Z is as defined in any one of paragraphs (104) to (111) above.

[0333] In a particular group of compounds of formula (IV): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (8e) or (15a) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; Y is as defined in paragraphs (34), (36), (39) and (40) above; Z is as defined in any one of paragraphs (104) to (111b) above.

[0334] In an embodiment of the compound of formula (IV): R 1a is as defined in paragraph (6) above; R 1b is as defined in any one of paragraphs (14a) to (14g) above; more suitably, R 1b is as defined in paragraphs (15a) to (15g) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; Y is as defined in any one of paragraphs (34) to (52a) above; Z is as defined in any one of paragraphs (104) to (111b) above.

[0335] In a particular group of compounds of formula (IV): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (15d), (15e), (15f) or (15g) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; Y is as defined in any one of paragraphs (34), (34a), (36), (39) and (40) above; Z is as defined in any one of paragraphs (104) to (111b) above.

[0336] In a particular group of compounds of formula (IV): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (15g); R 1a’is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; Y is as defined in any one of paragraphs (34), (36), (39) and (40) above; more suitably, Y is as defined in paragraph (52a) above; Z is as defined in any one of paragraphs (111) to (111b) above; more suitably, Z is as defined in paragraph (111b) above.

[0337] In a particular group of compounds of the present invention, X is as defined in paragraph (20) and Y is as defined in paragraph (34), i.e., the compound has structural formula (V) (a subdefinition of formula (I)) as shown below: [ka] [In the formula, R 1a , R 1b , R 1a’ , R 2a , R 3a1 , R 3a2 , n and Z each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0338] In an embodiment of the compound of formula (V): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (1), (2) and (7) through (15g) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) and (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104) to (111) above.

[0339] In an embodiment of the compound of formula (V): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraphs (15) and (15a) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0340] In a particular group of compounds of formula (V): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b As defined in paragraphs (8a) to (8e) or (15a) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) and (31) above; R3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104) to (111) above.

[0341] In a particular group of compounds of formula (V): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (8e) or (15a) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0342] In an embodiment of the compound of formula (V): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (15g) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104k) and (104) through (106) above.

[0343] In a particular group of compounds of formula (V): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (15g) above; R 1a’ is as defined in paragraphs (16) and (17) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) and (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104k) and (104) through (111) above.

[0344] In a particular group of compounds of formula (V): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (15g) above; R 1a’ is as defined in paragraph (17) above; R 2a is as defined in paragraph (19) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in paragraph (111b) above

[0345] In a particular group of compounds of the invention, X is as defined in paragraph (20) and R 1a’ is as defined in paragraph (17) and Y is as defined in paragraph (36), i.e., the compound has structural formula (VI) (a subdefinition of formula (I)) as shown below: [ka] [In the formula, R 1a , R 1b , R 2a , R 3b1 , R 3b2 , n and Z each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0346] In an embodiment of the compound of formula (VI): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (1), (2) and (7) through (15g) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3b1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3b2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104k) or (104) through (111) above.

[0347] In certain embodiments of compounds of Formula (VI): R 1ais as defined in paragraph (6) above; R 1b is as defined in paragraph (15) or (15a) above; R 2a is as defined in paragraph (19) above; R 3b1 is as defined in paragraph (28) above; R 3b2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0348] In a particular group of compounds of formula (VI): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (8a) to (8e) or (15a) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3b1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3b2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (104) to (111b) above.

[0349] In a particular group of compounds of formula (VI): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (8e) or (15a) above; R 2ais as defined in paragraph (19) above; R 3b1 is as defined in paragraph (28) above; R 3b2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104) to (106) above.

[0350] In certain embodiments of compounds of Formula (VI): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraphs (15) to (15g) above; R 2a is as defined in paragraph (19) above; R 3b1 is as defined in paragraph (28) above; R 3b2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in any one of paragraphs (104k), (104) through (106a), and (111) through (111b) above.

[0351] In a particular group of compounds of formula (VI): R 1a is as defined in any one of paragraphs (1) to (6) above; R 1b is as defined in any one of paragraphs (15) to (15g) above; R 2a is as defined in any one of paragraphs (18)-(19) above; R 3b1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3b2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; Z is as defined in any one of paragraphs (105) to (106a) and (111b).

[0352] In a particular group of compounds of formula (VI): R 1a is as defined in paragraph (6) above; R 1b is as defined in paragraph (15g) above; R 2a In a particular group of compounds of formula (VI): as defined in paragraph (19) above; R 3b1 is as defined in paragraph (28) above; R 3b2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; Z is as defined in paragraph (111b) above

[0353] In a particular group of compounds of the present invention, Y is as defined in paragraph (34) and Z is as defined in paragraph (106), i.e., the compound has structural formula (VII) (a subdefinition of formula (I)) as shown below: [ka] [In the formula, X, R 3a1 , R 3a2 , n, A5 and A6 each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0354] In an embodiment of the compound of formula (VII): X is as defined in any one of paragraphs (20) to (24) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; A5 is as defined in any one of paragraphs (76), (77) and (81) above; A6 is as defined in any one of paragraphs (78) to (81) above.

[0355] In an embodiment of the compound of formula (VII): X is as defined in paragraph (20) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A5 is as defined in paragraph (77) above; A6 is as defined in paragraph (79) above, or A6 is as defined in paragraph (79a) above.

[0356] In a particular group of compounds of formula (VII): X is as defined in any one of paragraphs (20) to (22) above, and R 1b , R 1d and R 1f are each as defined in any one of paragraphs (8a) through (8e) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; A5 is as defined in any one of paragraphs (76), (77) and (81) above; A6 is as defined in any one of paragraphs (78) to (81) above.

[0357] In a particular group of compounds of formula (VII): X is as defined in paragraph (20) above, and R 1b is as defined in any one of paragraphs (8a) to (8e) above; R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A5 is as defined in paragraph (77) above; A6 is as defined in paragraph (79) above.

[0358] In a particular group of compounds of formula (VII): X is as defined in paragraph (20) above, and R 1a , R 1b , R 1a’ and R 2a is hydrogen and R 1b is as defined in any one of paragraphs (15e) to (15g) above, and suitably R 1b is as defined in paragraph (15g); R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A3 is as defined in paragraph (71) above; A4 is as defined in paragraph (74) above; R7 is as defined in paragraph (66) above; R8 is as defined in paragraph (68) above.

[0359] In a particular group of compounds of the present invention, Y is as defined in paragraph (34) and Z is as defined in paragraph (105), i.e., the compound has structural formula (VIII) (a subdefinition of formula (I)) as shown below: [ka] [In the formula, X, R 3a1 , R 3a2 , n, A3, A4, R7 and R8 each have any of the meanings defined herein. or a pharmaceutically acceptable salt thereof.

[0360] In an embodiment of the compound of formula (VIII): X is as defined in any one of paragraphs (20)-(24) and (24a) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; A3 is as defined in any one of paragraphs (70), (71), (72) and (75) above; A4 is as defined in any one of paragraphs (73) to (75) above; R7 is as defined in any one of paragraphs (65), (66) and (69) above; R8 is as defined in any one of paragraphs (67), (68) and (69) above.

[0361] In an embodiment of the compound of formula (VIII): X is as defined in paragraph (20) above; R 3a1 is as defined in paragraph (28) above; R 3a2is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A3 is as defined in paragraph (71) above; A4 is as defined in paragraph (74) above; R7 is as defined in paragraph (66) above; R8 is as defined in any one of paragraphs (68) above.

[0362] In a particular group of compounds of formula (VIII): X is as defined in any one of paragraphs (20) to (22) above, and R 1b , R 1d and R 1f are each as defined in any one of paragraphs (8a) through (8e) above; R 3a1 is as defined in any one of paragraphs (25) to (28) and paragraphs (30) to (31) above; R 3a2 is as defined in any one of paragraphs (25), (29), (30) and (31) above; n is as defined in any one of paragraphs (32) and (33) above; A3 is as defined in any one of paragraphs (70), (71), (72) and (75) above; A4 is as defined in any one of paragraphs (73) to (75) above; R7 is as defined in any one of paragraphs (65), (66) and (69) above; R8 is as defined in any one of paragraphs (67), (68) and (69) above.

[0363] In a particular group of compounds of formula (VIII): X is as defined in any one of paragraphs (20) and R 1b is as defined in any one of paragraphs (8a) to (8e) above; R 3a1is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A3 is as defined in paragraph (71) above; A4 is as defined in paragraph (74) above; R7 is as defined in paragraph (66) above; R8 is as defined in paragraph (68) above.

[0364] In a particular group of compounds of formula (VIII): X is as defined in paragraph (20) above, and R 1a , R 1b , R 1a’ and R 2a is hydrogen and R 1b is as defined in any one of paragraphs (15e) to (15g) above, and suitably R 1b is as defined in paragraph (15g); R 3a1 is as defined in paragraph (28) above; R 3a2 is as defined in paragraph (29) above; n is as defined in paragraph (33) above; A3 is as defined in paragraph (71) above; A4 is as defined in paragraph (74) above; R7 is as defined in paragraph (66) above; R8 is as defined in paragraph (68) above.

[0365] Particular compounds of the present invention include any of the compounds set forth herein or a pharmaceutically acceptable salt thereof, and in particular any of the following: N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-6-(1H-pyrazol-5-yl)-1H-indazole-4-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; 6-ethynyl-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyanoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 8-Methoxy-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-5-carboxamide; 7-chloro-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({8-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-pyrazolo[4,3-c]pyridine-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(2-hydroxy-1-{6-methylimidazo[1,2-a]pyridin-2-yl}ethyl)-1H-indazole-4-carboxamide; 4-(3-{imidazo[1,2-a]pyridin-2-yl}-2,5-dihydro-1H-pyrrole-1-carbonyl)-1H-indazole; N-[(6-{[(pyridin-3-yl)methyl]amino}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(1-methyl-1H-imidazol-4-yl)methyl]amino}imidazo[1,2a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-[[6-(3-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-({6-[(pyridin-3-yl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(piperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(acetamidomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate hydrochloride; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-hydroxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide dihydrochloride; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-formylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyclopropylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; and 2-(1H-indazol-4-yl)-5-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1,3,4-oxadiazole.

[0366] Particular compounds of the present invention include any of the compounds set forth herein or a pharmaceutically acceptable salt thereof, and in particular any of the following: N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-6-(1H-pyrazol-5-yl)-1H-indazole-4-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; 6-ethynyl-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyanoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 8-Methoxy-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-5-carboxamide; 7-chloro-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({8-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-pyrazolo[4,3-c]pyridine-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(2-hydroxy-1-{6-methylimidazo[1,2-a]pyridin-2-yl}ethyl)-1H-indazole-4-carboxamide; 4-(3-{imidazo[1,2-a]pyridin-2-yl}-2,5-dihydro-1H-pyrrole-1-carbonyl)-1H-indazole; N-[(6-{[(pyridin-3-yl)methyl]amino}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(1-methyl-1H-imidazol-4-yl)methyl]amino}imidazo[1,2a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-[[6-(3-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-({6-[(pyridin-3-yl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(piperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(acetamidomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate hydrochloride; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-hydroxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide dihydrochloride; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-formylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyclopropylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 2-(1H-indazol-4-yl)-5-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1,3,4-oxadiazole; N-{[6-(2-aminoethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl N-(2-{2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}ethyl)carbamate; N-benzyl-2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridine-6-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 7-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-amino-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]pyridine-3-carboxamide; N-({6-[(benzyloxy)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-methyl-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 8-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-Bromo-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]quinoline-3-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]ethyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 4-[5-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1,3,4-thiadiazol-2-yl]-1H-indazole; 4-[1-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; N-[(6-{[(3-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexyl-2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(pyridin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-methoxyphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4- chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[benzyl(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1S)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylpropan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(4,4,4-trifluorobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-4-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3,3,3-trifluoropropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenyloxetan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-cyclopropylphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-dimethylbutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(trifluoromethoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methanesulfonylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(3-phenylpyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylcyclopropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1,3-thiazol-5-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl 3-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-{[6-({[(4,4-difluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl 2-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(pyridin-3-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1,4-dioxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclopropylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-difluorocyclobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxetan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R,2R)-2-(trifluoromethyl)cyclopropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4,4-difluorocyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({bicyclo[1.1.1]pentan-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2S)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2R)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-difluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(oxolan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 3-methyl-2-[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]butanoate; N-[(6-{[(oxan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclobutylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(tert-butylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-fluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(diethylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(pyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(pyridin-2-yl)azetidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(dicyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[4-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[({spiro[2.2]pentan-1-yl}methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(5,5-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3-methoxypropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4,4-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclopentyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(propylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(tert-butoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(oxan-2-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-benzylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenoxypiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-difluorocyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-dimethylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-methyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-tert-butylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-tert-butylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopentylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[4-(2,2-dimethylpropanoyl)piperazin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-acetylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({7-azabicyclo[2.2.1]heptan-7-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,2-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,3,3-trimethylbutan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(5-fluoropyridin-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({[1,1'-bi(cyclopropan)]-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,6-dimethylmorpholin-4-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 1-({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)piperidine-3-carboxylate; N-[(6-{[(2-fluoro-2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoro-4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-hydroxycyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopentylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclobutylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(3,3-difluorocyclobutyl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2S)-3,3-dimethylbutan-2-yl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({6-azaspiro[2.5]octan-6-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(1r,3r)-3-fluorocyclobutyl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(2-phenylethyl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(benzylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(cyclohexylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(phenylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(azetidin-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-chromene-2-carboxamide; N-{[6-({[(4-chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-[(7-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]cyclopropyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(2-amino-3-phenylpropyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; (cyclohexylmethyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; N-(cyclohexylmethyl)-2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridine-6-carboxamide; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; 4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl][(3,3-difluorocyclobutyl)methyl]amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](2,2-dimethylpropyl)amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](cyclohexylmethyl)amine; 6-bromo-4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; (2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methanol; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; ((cyclohexylmethyl)[1-(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)ethyl]amine; (2,2-dimethylpropyl)({2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amine; {2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methanol; N-({6-[(3R,5S)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({6-[4-(2,2-dimethylpropyl)morpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-methylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; and N-{[6-(9-Methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide.

[0367] Particular compounds of the present invention include any of the compounds set forth herein or a pharmaceutically acceptable salt thereof, and in particular any of the following: N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-6-(1H-pyrazol-5-yl)-1H-indazole-4-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-Bromo-N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; 6-ethynyl-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyanoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 8-Methoxy-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-5-carboxamide; 7-chloro-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({8-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-pyrazolo[4,3-c]pyridine-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(2-hydroxy-1-{6-methylimidazo[1,2-a]pyridin-2-yl}ethyl)-1H-indazole-4-carboxamide; 4-(3-{imidazo[1,2-a]pyridin-2-yl}-2,5-dihydro-1H-pyrrole-1-carbonyl)-1H-indazole; N-[(6-{[(pyridin-3-yl)methyl]amino}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(1-methyl-1H-imidazol-4-yl)methyl]amino}imidazo[1,2a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-[[6-(3-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-({6-[(pyridin-3-yl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(piperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(acetamidomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate hydrochloride; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-hydroxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide dihydrochloride; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-formylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyclopropylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 2-(1H-indazol-4-yl)-5-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1,3,4-oxadiazole; N-{[6-(2-aminoethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl N-(2-{2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}ethyl)carbamate; N-benzyl-2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridine-6-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 7-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-amino-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]pyridine-3-carboxamide; N-({6-[(benzyloxy)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-methyl-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 8-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-Bromo-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]quinoline-3-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]ethyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 4-[5-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1,3,4-thiadiazol-2-yl]-1H-indazole; 4-[1-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; N-[(6-{[(3-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexyl-2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(pyridin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-methoxyphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4- chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[benzyl(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1S)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylpropan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(4,4,4-trifluorobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-4-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3,3,3-trifluoropropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenyloxetan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-cyclopropylphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-dimethylbutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(trifluoromethoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methanesulfonylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(3-phenylpyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylcyclopropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1,3-thiazol-5-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl 3-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-{[6-({[(4,4-difluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-Butyl 2-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(pyridin-3-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1,4-dioxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclopropylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-difluorocyclobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxetan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R,2R)-2-(trifluoromethyl)cyclopropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4,4-difluorocyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({bicyclo[1.1.1]pentan-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2S)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2R)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-difluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(oxolan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 3-methyl-2-[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]butanoate; N-[(6-{[(oxan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclobutylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(tert-butylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-fluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(diethylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(pyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(pyridin-2-yl)azetidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(dicyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[4-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[({spiro[2.2]pentan-1-yl}methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(5,5-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3-methoxypropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4,4-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclopentyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(propylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(tert-butoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(oxan-2-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-benzylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenoxypiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-difluorocyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-dimethylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-methyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-tert-butylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-tert-butylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopentylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[4-(2,2-dimethylpropanoyl)piperazin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-acetylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({7-azabicyclo[2.2.1]heptan-7-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,2-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,3,3-trimethylbutan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(5-fluoropyridin-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({[1,1'-bi(cyclopropan)]-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,6-dimethylmorpholin-4-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 1-({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)piperidine-3-carboxylate; N-[(6-{[(2-fluoro-2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoro-4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-hydroxycyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopentylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclobutylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(3,3-difluorocyclobutyl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2S)-3,3-dimethylbutan-2-yl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({6-azaspiro[2.5]octan-6-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(1r,3r)-3-fluorocyclobutyl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(2-phenylethyl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(benzylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(cyclohexylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(phenylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(azetidin-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-chromene-2-carboxamide; N-{[6-({[(4-chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-[(7-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]cyclopropyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(2-amino-3-phenylpropyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; (cyclohexylmethyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; N-(cyclohexylmethyl)-2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridine-6-carboxamide; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; 4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl][(3,3-difluorocyclobutyl)methyl]amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](2,2-dimethylpropyl)amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](cyclohexylmethyl)amine; 6-bromo-4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; (2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methanol; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; ((cyclohexylmethyl)[1-(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)ethyl]amine; (2,2-dimethylpropyl)({2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amine; {2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methanol; N-({6-[(3R,5S)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({6-[4-(2,2-dimethylpropyl)morpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-methylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-ol; 4-[1-[[6-[[(1-hydroxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-ol; 1-[[[2-[[4-(5-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[[[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclobutylmethyl)-1-[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-(cyclobutylmethyl)-1-[2-[[4-(5-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 4-[1-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]triazol-4-yl]-1H-indazol-3-amine; N-[[6-[[(1-methoxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(1,4-oxazepan-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-cyano-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[3.3]heptan-2-ylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[2.3]hexan-5-ylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(1-bicyclo[1.1.1]pentanylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[2.3]hexan-2-ylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-methoxy-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-methylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(butylaminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-hydroxycyclopentyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-methylbutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-cyclobutylethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-hydroxy-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-hydroxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-hydroxybutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3-methylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3,3-dimethylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2,2-dimethylbutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(2S)-2-methylbutyl]amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[[[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; 1-[[[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carboxylic acid; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carboxamide; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-N,N-dimethyl-1H-indazole-6-carboxamide; [4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-yl]-morpholino-methanone; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-N-(2-hydroxyethyl)-1H-indazole-6-carboxamide; 1-[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 1-[[[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-[[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]-2,2-dimethyl-propan-1-amine; N-(cyclobutylmethyl)-1-[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; N-(cyclohexylmethyl)-1-[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclopentanamine; N-[[6-[(4,4-dimethyl-1-piperidyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-5-fluoro-4-oxo-chromene-2-carboxamide; N-(cyclobutylmethyl)-1-[2-[[4-(6-morpholino-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 6-[2-(2-aminoethoxy)ethoxy]-N-[[6-[(4,4-dimethyl-1-piperidyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-[[6-[1-(cyclobutylmethylamino)-2-phenyl-ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[1-[bis(cyclobutylmethyl)amino]-2-phenyl-ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[2-[[4-(7-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 1-[[[2-[[4-(7-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; [2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanol; N-(cyclobutylmethyl)-1-[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclohexylmethyl)-1-[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-[[2-[[4-(6-cyclopropyl-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]-2,2-dimethyl-propan-1-amine; N-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-(cyclobutylmethyl)-1-[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-(cyclohexylmethyl)-1-[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclobutylmethyl)-1-[2-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; 2-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]-6-methyl-imidazo[1,2-a]pyridine; N-[[6-[2-cyano-1-(cyclobutylmethylamino)ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(6-methylmorpholin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(7-bromo-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-piperazin-2-ylimidazo[1,2-a]pyridin-2-yl)methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(6-cyclohexyl-4-oxo-2-piperidyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[2-(1H-indazol-4-yl)thiazol-5-yl]-1-(6-methylimidazo[1,2-a]pyridin-2-yl)ethanol; 2-[[1-(1H-indazol-4-yl)triazol-4-yl]methyl]imidazo[1,2-a]pyridine; N-[(3,3-difluorocyclobutyl)methyl]-1-[2-[[1-(1H-indazol-4-yl)triazol-4-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carbonitrile; N-(cyclobutylmethyl)-1-[2-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-[[6-[[acetyl(cyclobutylmethyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(cyclobutylmethyl)-1-[2-[[3-(1H-indazol-4-yl)-1,2,4-triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 2-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]pyrido[1,2-a]pyrimidin-4-one; N-[[6-[(2-bicyclo[2.2.1]hept-5-enylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(1R,2R,4S)-norbornan-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(1R,2S,4S)-norbornan-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-azabicyclo[2.2.1]heptan-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-azabicyclo[2.2.2]octan-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2,2-difluorospiro[3.3]heptan-6-yl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[[[rac-(1S,2S,4S)-7-oxabicyclo[2.2.1]hept-5-en-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[[[rac-(1S,2R,4S)-7-oxabicyclo[2.2.1]hept-5-en-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; and N-[(1-Methoxycyclobutyl)methyl]-1-[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine.

[0368] The various functional groups and substituents modifying the compound of formula (I) are typically selected so that the molecular weight of the compound of formula (I) does not exceed 1000. More typically, the molecular weight of the compound is less than 900, e.g., less than 800, or less than 750, or less than 700, or less than 650. More preferably, the molecular weight is less than 600, e.g., 550 or less.

[0369] Suitable pharmaceutically acceptable salts of the compounds of the present invention are, for example, acid addition salts of compounds of the present invention that are sufficiently basic, for example, acid addition salts with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid, methanesulfonic acid, or maleic acid. Furthermore, suitable pharmaceutically acceptable salts of compounds of the present invention that are sufficiently acidic are alkali metal salts, for example, sodium salts or potassium salts, alkaline earth metal salts, for example, calcium salts or magnesium salts, ammonium salts, or salts with organic bases that provide pharmaceutically acceptable cations, for example, salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine, or tris-(2-hydroxyethyl)amine.

[0370] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, when it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by being designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0371] The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds can be prepared as individual (R)- or (S)-stereoisomers or mixtures thereof. Unless otherwise specified, the description and naming of a particular compound in the present specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise. Methods for the determination of stereochemistry and the separation of stereoisomers are known in the art (see Chapter 4 of "Advanced Organic Chemistry," 4th edition J. March, John Wiley and Sons, New York, 2001), for example, by synthesis from optically active starting materials or by resolution of racemates. Some compounds of the present invention may have geometric isomeric centers (E- and Z-isomers). It should be understood that all optical, diastereomeric, and geometric isomers and mixtures thereof that possess antiproliferative activity are encompassed.

[0372] The present invention also includes compounds of the invention as defined herein that contain one or more isotopic substitutions. For example, H is 1 H, 2 H(D) and 3 H can be in any isotopic form, including T; C 12 C. 13 C and 14 It can be any isotopic form, including C; O 16 O and 18 It can be any isotopic form containing O; and the like.

[0373] It should also be understood that certain compounds of formula (I) (and compounds of formulas (II), (III), and (IV)) can exist in solvated and unsolvated forms, such as, for example, hydrated forms. It should be understood that the present invention encompasses all such solvated forms that possess antiproliferative activity.

[0374] It is also to be understood that certain compounds of formula (I) (and compounds of formula (II), formula (III) and formula (IV)) may exhibit polymorphism, and that the invention encompasses all such forms which possess antiproliferative activity.

[0375] Compounds of formula (I) (and compounds of formulas (II), (III), and (IV)) may exist in several tautomeric forms, and references to compounds of formula (I) include all such forms. For the avoidance of doubt, even if a compound may exist in one of several tautomeric forms and only one of them is specifically described or shown, all other forms are encompassed by formula (I). Examples of tautomeric forms include keto, enol, and enolate forms, such as in the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / acinitro. [ka]

[0376] Compounds of formula (I) containing an amine functional group can also form N-oxides. Reference herein to compounds of formula (I) containing an amine functional group also includes N-oxides. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are the N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid). See, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 1977. More specifically, N-oxides can be prepared by the method of LW Deady (Syn. Comm. 1977, 7, 509-514), which involves reacting an amine compound with m-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0377] The compounds of formula (I) may be administered in the form of prodrugs that are broken down in the human or animal body to liberate the compounds of the present invention. Prodrugs may be used to alter the physical properties and / or pharmacokinetic properties of the compounds of the present invention. Prodrugs may be formed when the compounds of the present invention have a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include in vivo cleavable ester derivatives that may be formed at the carboxy or hydroxy group of the compounds of formula (I) and in vivo cleavable amide derivatives that may be formed at the carboxy or amino group of the compounds of formula (I).

[0378] Thus, the present invention includes compounds of formula I, as defined below, when available by organic synthesis and when available in the human or animal body by cleavage of a prodrug. Thus, the present invention includes compounds of formula (I) prepared by organic synthetic means, and also includes such compounds produced in the human or animal body by metabolism of precursor compounds. That is, compounds of formula (I) can be synthetically produced compounds or metabolically produced compounds.

[0379] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) are those prodrugs that, based on sound medical judgment, are suitable for administration to the human or animal body without undesired pharmacological activity and without undue toxicity.

[0380] Various forms of prodrugs have been described, for example, in: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", ACS Symposium Series, Volume 14; and h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.

[0381] Suitable pharmaceutically acceptable prodrugs of a compound of formula (I) having a carboxy group are, for example, in vivo cleavable esters thereof. In vivo cleavable esters of a compound of formula (I) containing a carboxy group are, for example, pharmaceutically acceptable esters that cleave in the human or animal body to produce the original acid. Suitable pharmaceutically acceptable esters of carboxy include C esters such as methyl, ethyl, and tert-butyl. 1-6 C such as alkyl esters and methoxymethyl esters 1-6 C such as alkoxymethyl esters and pivaloyloxymethyl esters 1-6C such as alkanoyloxymethyl esters, 3-phthalidyl esters, cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters 3-8 Cycloalkylcarbonyloxy-C 1-6 C alkyl esters, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, and C alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl esters. 1-6 Alkoxycarbonyloxy-C 1-6 Contains alkyl esters.

[0382] Suitable pharmaceutically acceptable prodrugs of the compound of formula (I) having a hydroxy group are, for example, in vivo cleavable esters or ethers thereof. The in vivo cleavable esters or ethers of the compound of formula (I) containing a hydroxy group are, for example, pharmaceutically acceptable esters or ethers that are cleaved in the human or animal body to produce the original hydroxy compound. Suitable groups for the hydroxy group that form pharmaceutically acceptable esters include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable groups for the hydroxy group that form pharmaceutically acceptable esters include C alkyl esters such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. 1-10 Alkanoyl groups, C such as ethoxycarbonyl 1-10 Alkoxycarbonyl group, N,N-(C 1-6 ) 2 carbamoyl, 2-dialkylaminoacetyl, and 2-carboxyacetyl groups. Examples of ring substituents for the phenylacetyl and benzoyl groups are aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C 1-4 Groups for a hydroxy group which form suitable pharmaceutically acceptable ethers include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0383] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) having a carboxy group include, for example, in vivo cleavable amides thereof, amines such as ammonia, C groups such as methylamine, 1-4 (C) such as alkylamines, dimethylamine, N-ethyl-N-methylamine or diethylamine 1-4 C alkyl) 2 amines, such as 2-methoxyethylamine 1-4 Alkoxy-C 2-4 Phenyl-C alkylamines, such as benzylamine 1-4 Amides formed with alkylamines and amino acids such as glycine or their esters.

[0384] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides derived from an amino group include, for example, C acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. 1-10 Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C 1-4 alkyl)piperazin-1-ylmethyl.

[0385] The in vivo effects of compounds of formula (I) may be exerted in part by one or more metabolic products formed in the human or animal body following administration of a compound of formula (I). As noted above, the in vivo effects of compounds of formula (I) may also be exerted by metabolism of a precursor compound (prodrug).

[0386] The present invention may relate to any compound or particular group of compounds defined herein otherwise with respect to any preferred or suitable feature or particular embodiment, but the present invention may also relate to any compound or particular group of compounds that specifically excludes said any preferred or suitable feature or particular embodiment.

[0387] Suitably, the present invention excludes any individual compound that does not have biological activity as defined herein.

[0388] synthesis The compounds of the present invention may be prepared by any suitable technique in the art. Certain methods for preparing these compounds are further described in the accompanying examples.

[0389] In the description of synthetic methods provided herein, and in any referenced synthetic methods used to prepare starting materials, it should be understood that all indicated reaction conditions, including solvents, reaction atmospheres, reaction temperatures, experimental times, and work-up methods, can be selected by one of ordinary skill in the art.

[0390] It is understood by one skilled in the art of organic synthesis that the substituents present on various positions of the molecule must be compatible with the reagents and reaction conditions used.

[0391] It is understood that during the synthesis of the compounds of the invention in the manner defined herein, or during the synthesis of particular starting materials, it may be desirable to protect certain substituents to prevent them from reacting undesirably. The experienced chemist will understand when such protection is necessary and how such protecting groups may be introduced and subsequently removed.

[0392] For examples of protecting groups, see, for example, one of the many general texts on the subject, such as 'Protective Groups in Organic Synthesis' by Theodora Green (published by John Wiley & Sons). Protecting groups may be removed, as required for removal of the protecting group in question, by any convenient method described in the literature or known to the experienced chemist, such method being chosen so as to effect removal of the protecting group with minimal effect on groups elsewhere in the molecule.

[0393] If reactants contain groups such as amino, carboxy or hydroxy, it may be desirable to protect them in some of the reactions mentioned herein.

[0394] For example, suitable protecting groups for amino or alkylamino groups are, for example, acyl groups, such as alkanoyl groups, for example acetyl, alkoxycarbonyl groups, for example methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl groups, arylmethoxycarbonyl groups, for example benzyloxycarbonyl, or aroyl groups, for example benzoyl.The deprotection conditions for the above-mentioned protecting groups necessarily vary with the selection of protecting groups.Thus, for example, acyl groups, such as alkanoyl, or alkoxycarbonyl groups or aroyl groups, can be removed, for example, by hydrolysis, using a suitable base, such as alkali metal hydroxide, for example lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups may be removed by treatment with a suitable acid, such as hydrochloric, sulfuric, or phosphoric acid, or trifluoroacetic acid, and arylmethoxycarbonyl groups such as benzyloxycarbonyl groups may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid, for example, tris(trifluoroacetate)borane. Another suitable protecting group for a primary amino group is, for example, a phthaloyl group, which may be removed by treatment with an alkylamine, for example, dimethylaminopropylamine, or hydrazine.

[0395] Suitable protecting groups for hydroxy groups include, for example, acyl groups, e.g., alkanoyl groups such as acetyl, aroyl groups such as benzoyl, or arylmethyl groups such as benzyl. The deprotection conditions for the above protecting groups necessarily vary depending on the choice of protecting group. Thus, acyl groups such as alkanoyl or aroyl groups can be removed, for example, by hydrolysis using a suitable base such as an alkali metal hydroxide, e.g., lithium hydroxide, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups such as benzyl groups can be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.

[0396] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example, a methyl or ethyl group which may be removed by hydrolysis with a base such as sodium hydroxide, or for example, a t-butyl group which may be removed by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example, a benzyl group which may be removed by hydrogenation over a catalyst such as palladium on carbon.

[0397] Resins can also be used as protecting groups.

[0398] The methods used to synthesize compounds of formula I will vary depending on the nature of the variables, and suitable methods for their preparation are further described in the accompanying examples.

[0399] Once a compound of formula I has been synthesized by any one of the methods defined herein, the method may then comprise the further step of: (i) removal of any protecting groups present; (ii) converting a compound of formula I into another compound of formula I; (iii) the formation of a pharmaceutically acceptable salt, hydrate or solvate of the compound; and / or (IV) Formation of a prodrug of the compound Further includes:

[0400] The resulting compound of formula I is isolated and purified using techniques known in the art.

[0401] biological activity The METTL3 enzyme and cellular assays described in the accompanying Examples section can be used to measure the pharmacological effects of compounds of the invention.

[0402] Although the pharmacological properties of compounds of formula I vary with structural variation, as expected, compounds of the invention were found to be active in these METTL3 assays.

[0403] Generally, compounds of the present invention have an IC of 10 μM or less in the METTL3 enzyme assay described herein. 50 and preferred compounds of the present invention exhibit an IC 50 and most preferred compounds of the present invention exhibit an IC 50 Shows.

[0404] In the METTL3 cell assay described in the Examples section, compounds of formula (I) suitably have an activity of less than 10 μM, with preferred compounds of the invention exhibiting an activity of 5 μM or less and most preferred compounds of the invention exhibiting an activity of 2 μM or less.

[0405] Pharmaceutical Composition According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the invention as defined above, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0406] Compositions of the invention may be in a form suitable for oral use (e.g., tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as a cream, ointment, gel, or aqueous or oily solution or suspension), administration by inhalation (e.g., as a finely divided powder or liquid aerosol), administration by insufflation (e.g., as a finely divided powder) or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as a suppository for rectal administration).

[0407] The compositions of the present invention can be obtained by conventional methods using conventional pharmaceutical excipients known in the art. Thus, compositions intended for oral use can contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.

[0408] An effective amount of a compound of the invention for use in therapy is an amount sufficient to treat or prevent a proliferative condition and / or to treat or prevent an autoimmune disease referred to herein, slow its progression and / or reduce the symptoms associated with said condition and / or disease.

[0409] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending on the individual treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, 0.5 mg to 0.5 g of active agent (more suitably, 0.5 to 100 mg, e.g., 1 to 30 mg) of the compound, and an appropriate and convenient amount of excipient, which can vary from about 5 to about 98 weight percent of the total composition.

[0410] The magnitude of a dose of a compound of formula (I) for therapeutic or prophylactic purposes will vary, in accordance with known medical principles, with the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration.

[0411] When using the compounds of the present invention for therapeutic or prophylactic purposes, they are generally administered so that a daily dose is received, for example, in the range of 0.1 mg / kg to 75 mg / kg body weight, if divided doses are necessary. Generally, when parenteral routes are used, lower doses are administered. Thus, for example, for intravenous or intraperitoneal administration, a dose in the range of, for example, 0.1 mg / kg to 30 mg / kg body weight is generally used. Similarly, for administration by inhalation, a dose in the range of, for example, 0.05 mg / kg to 25 mg / kg body weight is used. Oral administration may also be appropriate, particularly in tablet form. Typically, a unit dosage form contains about 0.5 mg to 0.5 g of the compound of the present invention.

[0412] Therapeutic Uses and Applications The present invention provides compounds that function as inhibitors of METTL3 activity.

[0413] Thus, the present invention provides a method for inhibiting METTL3 activity in vitro or in vivo, comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0414] The present invention also provides a method for treating a disease or disorder associated with METTL3 activity in a patient in need of treatment, comprising administering to said patient a therapeutically effective amount of a compound or its pharmaceutically acceptable salt or a pharmaceutical composition as defined herein.Suitably, the disease or disorder associated with METTL3 activity is cancer such as lung cancer, kidney cancer, solid organ cancer, pancreatic cancer or leukemia, type 2 diabetes, neuropsychiatric behavioral disorder or depressive disorder.

[0415] The present invention provides a method for inhibiting cell proliferation in vitro or in vivo, comprising contacting a cell with an effective amount of a compound defined herein, or a pharmaceutically acceptable salt thereof.

[0416] The present invention provides a method for treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0417] The present invention provides a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Suitably, the cancer is lung cancer, kidney cancer, solid organ cancer, pancreatic cancer, or leukemia, suitably AML leukemia or chronic myeloid leukemia.

[0418] The present invention provides a method for treating leukemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0419] The present invention provides a method for treating AML leukemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0420] The present invention provides a method for treating an autoimmune disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Suitably, the autoimmune disease is colitis, multiple sclerosis, rheumatoid arthritis, lupus, cirrhosis, or dermatitis.

[0421] The present invention provides a method for treating neurological disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0422] The present invention provides a method for treating an infectious disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0423] The present invention provides a method for treating inflammatory diseases, comprising administering to a subject in need thereof a therapeutically effective amount of a compound defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0424] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in therapy.

[0425] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in the treatment of a proliferative condition.

[0426] The present invention provides the compound defined herein or its pharmaceutically acceptable salt or pharmaceutical composition for use in treating cancer.In certain embodiments, cancer is human cancer.Suitably, cancer is lung cancer, kidney cancer, solid organ cancer, pancreatic cancer or leukemia, suitably AML leukemia or chronic myeloid leukemia.

[0427] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in the treatment of leukemia.

[0428] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in the treatment of AML leukemia.

[0429] The present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in inhibiting METTL3 activity.

[0430] The present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for use in the treatment of an autoimmune disease, suitably the autoimmune disease colitis, multiple sclerosis, rheumatoid arthritis, lupus, cirrhosis or dermatitis.

[0431] The present invention provides a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as defined herein for use in the treatment of a neurological disorder.

[0432] The present invention provides a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as defined herein for use in the treatment of infectious diseases.

[0433] The present invention provides a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as defined herein for use in the treatment of inflammatory diseases.

[0434] The present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder associated with METTL3 activity.Suitably, the disease or disorder associated with METTL3 activity is cancer, such as lung cancer, kidney cancer, solid organ cancer, pancreatic cancer or leukemia, type 2 diabetes, neuropsychiatric behavioral disorder or depressive disorder.

[0435] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative condition.

[0436] The present invention provides the use of the compound defined herein or its pharmaceutically acceptable salt in the manufacture of a medicament for the treatment of cancer.Suitably, the medicament is for use in the treatment of human cancer.Suitably, the cancer is lung cancer, kidney cancer, solid organ cancer, pancreatic cancer or leukemia, suitably AML leukemia or chronic myeloid leukemia.

[0437] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of leukemia.

[0438] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of AML leukemia.

[0439] The present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an autoimmune disease. Suitably, the autoimmune disease is colitis, multiple sclerosis, rheumatoid arthritis, lupus, cirrhosis or dermatitis.

[0440] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a neurological disorder.

[0441] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an inflammatory disease.

[0442] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an infectious disease.

[0443] The invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of METTL3 activity.

[0444] The present invention provides the use of the compound defined herein or its pharmaceutically acceptable salt in the manufacture of medicine for treating the disease or disorder associated with METTL3 activity.Suitably, the disease or disorder associated with METTL3 activity is cancer such as lung cancer, kidney cancer, solid organ cancer, pancreatic cancer or leukemia, type 2 diabetes, neuropsychiatric behavioral disorder, depressive disorder.

[0445] The term "proliferative disorder" is used interchangeably herein and refers to unwanted or uncontrolled excessive cell proliferation or undesired abnormal cell growth, e.g., neoplastic or hyperplastic growth, whether in vitro or in vivo. Examples of proliferative conditions include premalignant and malignant cell growth, including, but not limited to, malignant neoplasms and tumors, cancer, leukemia, psoriasis, bone disease, fibroproliferative disorders (e.g., fibroproliferative disorders of connective tissue), and atherosclerosis. Any type of cell can be treated, including, but not limited to, lung, colon, breast, ovary, prostate, liver, pancreas, brain, and skin.

[0446] The antiproliferative effects of the compounds of the present invention (due to their improved inhibition of METTL3 activity) have particular application in the treatment of human cancers.

[0447] Anti-cancer effects may include one or more mechanisms including, but not limited to, controlling cell proliferation, inhibiting angiogenesis (the formation of new blood vessels), inhibiting metastasis (the spread of tumors from their source), inhibiting invasion (the spread of tumor cells into adjacent normal structures), or promoting apoptosis (programmed cell death).

[0448] In certain embodiments of the invention, the proliferative condition treated is cancer.

[0449] Administration route The compounds of the present invention or pharmaceutical compositions containing them may be administered to a subject by any convenient route of administration, whether systemically / peripherally or locally (ie, at the desired site of action).

[0450] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by patches, patches, etc.); transmucosal (including, e.g., by patches, patches, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., via aerosol, e.g., by inhalation or insufflation via the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, e.g., by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; and by implantation of a depot or reservoir, e.g., subcutaneously or intramuscularly.

[0451] Combination therapy The antiproliferative treatment defined above may be applied as a monotherapy or may comprise, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy, such chemotherapy comprising one or more of the following categories of antitumor agents: (i) Other antiproliferative / antineoplastic drugs and their combinations used in medical oncology, such as alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolomide, and nitrosoureas); antimetabolites (e.g., gemcitabine and antifolates, e.g., fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor antibiotics (e.g., adriamycin, anthracyclines such as ampicillin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin C, dactinomycin, and mithramycin; mitotic inhibitors (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, and taxoids such as taxol and taxotere, and polokinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan, and camptothecin); (ii) cytostatics, such as antiestrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene, and idoxifene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or agonists (e.g., goserelin, leuprorelin, and buserelin), progestogens (e.g., megestrol acetate), aromatase inhibitors (e.g., anastrozole, letrozole, vorazole, and exemestane), and 5α-reductase inhibitors such as finasteride; (iii) anti-invasive agents [e.g., 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application, Publication No. WO 01 / 94341), N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825); J. Med. Chem., 2004, 47 , 6658-6661) and c-Src kinase family inhibitors such as bosutinib (SKI-606) as well as metalloproteinase inhibitors such as marimastat, urokinase plasminogen activator receptor function inhibitors or antibodies to heparanase]; (iv) Growth factor function inhibitors: For example, such inhibitors include growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin TM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225], and Stern et al. (Critical reviews in oncology / haematology, 2005, Vol. 54, pp 11-29); such inhibitors also include tyrosine kinase inhibitors, for example, epidermal growth factor family inhibitors (e.g., N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI EGFR family tyrosine kinase inhibitors such as EGFR-1033, erbB2 tyrosine kinase inhibitors such as lapatinib; hepatocyte growth factor family inhibitors; insulin growth factor family inhibitors; platelet-derived growth factor family inhibitors such as imatinib and / or nilotinib (AMN107); serine / threonine kinase inhibitors (e.g., Ras / Raf signaling inhibitors, e.g., farnesyltransferase inhibitors, e.g., sorafenib (BAY43-9006), tipifarnib (R115777), and lonafarnib (S CH66336), inhibitors of cell signaling mediated by MEK and / or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; including cyclin-dependent kinase inhibitors such as Aurora kinase inhibitors (e.g., AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528, and AX39459) and CDK2 and / or CDK4 inhibitors; (v) Antiangiogenic agents, for example, antiangiogenic agents that inhibit the effects of vascular endothelial growth factor [e.g., anti-vascular endothelial growth factor antibody bevacizumab (Avastin)] TM) and, for example, vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW786034), and 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; see WO 00 / 47212 ). VEGF receptor tyrosine kinase inhibitors such as those described in Example 240), compounds such as those described in International Patent Applications WO 97 / 22596, WO 97 / 30035, WO 97 / 32856 and WO 98 / 13354, as well as compounds acting by other mechanisms (e.g., linomide, integrin αvβ3 function inhibitors and angiostatin); (vi) Vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99 / 02166, WO 00 / 40529, WO 00 / 41669, WO 01 / 92224, WO 02 / 04434 and WO 02 / 08213. (vii) endothelin receptor antagonists, such as zibotentan (ZD4054) or atrasentan; (viii) antisense therapy, e.g., antisense therapy directed to the targets listed above, e.g., ISIS 2503, anti-ras antisense; (ix) gene therapy approaches, including approaches to replace abnormal genes such as abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT (gene-directed enzyme prodrug therapy) approaches such as using cytosine deaminase, thymidine kinase, or bacterial nitroreductase enzymes, and approaches to improve patient tolerance to chemotherapy or radiation therapy, such as multidrug resistance gene therapy; (x) immunotherapy, including ex vivo and in vivo approaches to increase the immunogenicity of a patient's tumor cells, such as transfection with cytokines, e.g., interleukin 2, interleukin 4, or granulocyte-macrophage colony-stimulating factor, approaches to reduce T cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines, and approaches using anti-idiotypic antibodies; and (xi) Agents used in the treatment of AML leukemia, including, for example, cytarabine, FLT3 inhibitors, BCL2 inhibitors, or IDH1 / 2 inhibitors.

[0452] In certain embodiments, the antiproliferative treatment as defined above may comprise, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy.

[0453] Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of treatment. Such combination products utilize the compounds of this invention within the dosage ranges described above and the pharmaceutically active agent within its approved dosage range.

[0454] According to this aspect of the invention there is provided a combination for use in the treatment of cancer (e.g. cancer involving solid tumours) comprising a compound of the invention as defined above or a pharmaceutically acceptable salt thereof and another anti-tumour agent.

[0455] According to this aspect of the present invention, there is provided a combination comprising a compound of the invention as defined above, or a pharmaceutically acceptable salt thereof, and any one of the anti-tumour agents listed above, for use in the treatment of a proliferative condition, such as cancer (e.g., a cancer involving a solid tumour).

[0456] In a further aspect of the present invention, there is provided a compound of the present invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in combination with an anti-tumor agent selected from any of the anti-tumor agents listed above.

[0457] As used herein, when the term "combination" is used, it should be understood to refer to simultaneous, separate, or sequential administration. In one embodiment of the present invention, "combination" refers to simultaneous administration. In another embodiment of the present invention, "combination" refers to separate administration. In one embodiment of the present invention, "combination" refers to sequential administration. When administration is sequential or separate, delay in administration of the second component should not result in the loss of the benefits of the combination.

[0458] According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, in combination with an anti-tumour agent (optionally selected from the anti-tumour agents listed above), together with a pharmaceutically acceptable diluent or carrier.

[0459] In another embodiment, the invention relates to a therapeutic combination comprising a compound as defined herein and another agent used in the treatment of AML leukemia, such as cytarabine, an FLT3 inhibitor, a BCL2 inhibitor or an IDH1 / 2 inhibitor. [Example]

[0460] The following abbreviations are used in the examples: HATU-[dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylene]-dimethyl-ammonium;Hexafluorophosphate DIPEA-N-ethyl-N-isopropyl-propan-2-amine DEAD-Diethyl azodicarboxylate DMF - Dimethylformamide RT-retention time Phase sep Cartrige-Telos Phase Separator 6mL

[0461] Example 1: Characterization Methods The following HPLC method was used: [Table 1] [Table 2] [Table 3] [Table 4]

[0462] The following LCMS method was used: LCMS Method A refers to a low pH analysis using a mobile phase consisting of 0.1% formic acid in a gradient of 5-100% MeCN in water over 1.2 min at a flow rate of 1.2 mL / min. The stationary phase consisted of Kinetex Core-Shell C18, 2.1 mm x 50 mm, 5 μm. Experiments were performed at 40 °C.

[0463] LCMS Method B refers to a high pH analysis using a mobile phase consisting of 2 mM ammonium bicarbonate buffered to pH 10 in a gradient of 5-100% MeCN in water at a flow rate of 1.0 mL / min for 2.1 min. The stationary phase consisted of Phenomenex Gemini-NX C18, 2.0 x 50 mm, 3 μm. Experiments were performed at 40 °C.

[0464] LCMS Method C refers to a high pH analysis using a mobile phase consisting of 2 mM ammonium bicarbonate buffered to pH 10 in a gradient of 5-100% MeCN in water over 5.8 minutes at a flow rate of 0.6 mL / min. The stationary phase was a Waters UPLC® BEH TM The experiment was carried out at 40°C.

[0465] LCMS Method D refers to a high pH analysis in 5.9 minutes at a flow rate of 0.6 mL / min using a mobile phase consisting of 2 mM ammonium bicarbonate buffered to pH 10 in a gradient of 5-100% MeCN in water. The stationary phase consisted of Phenomenex Gemini-NX C18, 2.0 x 100 mm, 3 μm. Experiments were performed at 40 °C.

[0466] LCMS Method E refers to a low pH analysis using a mobile phase consisting of 0.1% formic acid in a gradient of 5-100% MeCN in water at a flow rate of 0.6 mL / min over 5.3 min. The stationary phase consisted of Phenomenex Kinetix-XB C18, 2.1 mm x 100 mm, 1.7 μm. Experiments were performed at 40 °C.

[0467] LCMS Method F refers to a high pH analysis using a mobile phase consisting of 2 mM ammonium bicarbonate buffered to pH 10 in a gradient of 5-100% MeCN in water over 0.75 min at a flow rate of 1.0 mL / min. The stationary phase was a Waters UPLC® BEH TM The experiment was carried out at 40°C.

[0468] Method G refers to a low pH analysis using a mobile phase consisting of 0.1% formic acid in water (pH = 2.70) in a gradient of 3-100% 0.1% formic acid:acetonitrile (10:90) in water at a flow rate of 0.8 mL / min for 3.00 min. The stationary phase consisted of a C18, 50*2.1 mm, 1.6 μm column. The experiment was performed at 35 °C.

[0469] Method H refers to a high pH analysis using a mobile phase consisting of 5 mM ammonium bicarbonate (pH 7.35) in a gradient of MeCN in water at a flow rate of 0.5 mL / min for 3.0 min. The stationary phase consisted of C18, 50*2.1 mm, 2.5 μm. The experiment was performed at 35°C.

[0470] Method I refers to a 3.0-minute high-pH run at a flow rate of 0.5 mL / min using a mobile phase consisting of 5 mM ammonium bicarbonate (pH 7.35) in a gradient of MeCN in water. The stationary phase consisted of C18, 50*2.1 mm, 2.5 μm. The experiment was performed at 35°C.

[0471] The following preparative HPLC method was used: Preparative method A refers to a 14.4-minute low-pH purification using a mobile phase consisting of 0.1% formic acid in a gradient of 10–95% MeCN in water at a flow rate of 40 mL / min. The stationary phase consisted of a Waters Sunfire C18, 30 × 100 mm, 10 μm.

[0472] Preparative method B refers to a 10-minute high-pH purification using a mobile phase consisting of 0.2% ammonium hydroxide in a gradient of 30-95% MeCN in water at a flow rate of 40 mL / min. The stationary phase was Waters XBridge TM C18 OBD TM , 30 × 100 mm, 10 μm.

[0473] Example 2: Chemical synthesis and characterization Intermediate 1: Synthesis of 6-bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylic acid [ka] Step 1: Methyl 6-bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylate [ka] Methyl 6-bromo-1H-indazole-4-carboxylate (1.0 g, 3.92 mmol) and TsOH.HO (75 mg, 0.39 mmol) were mixed in DCM (40 mL) and 3,4-dihydro-2H-pyran (1.07 mL, 11.8 mmol) was added. The mixture was stirred at room temperature for 20 minutes, during which time the mixture turned dark. The mixture was quenched with aqueous sodium bicarbonate (saturated, 100 mL), and the mixture was stirred vigorously for 5 minutes. The phases were separated, the aqueous phase was extracted with DCM (3 × 80 mL), and the combined organic extracts were dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel chromatography (Biotage 50 g, eluting with 0–50% ethyl acetate / heptane) to give the title compound as a white solid (1.26 g, 92%). LCMS Method A (electrospray): m / z = 338.9 / 340.9 (M+H)+ , RT=1.34 minutes.

[0474] Step 2: 6-Bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylic acid A solution of 6-bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylate (600 mg, 1.77 mol) in THF (10 ml) and water (10 ml) was treated with lithium hydroxide (132 mg, 5.31 mmol) and the mixture was heated at 60° C. for 90 minutes. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with water (10 ml) and acidified to approximately pH 1 with 1 M HCl (aqueous). The mixture was then extracted with chloroform / isopropanol (3:1, 4×30 ml) and the combined organic extracts were dried over sodium sulfate and evaporated in vacuo to give the title compound as a white solid (566 mg, 97%). LCMS Method A (electrospray): m / z = 324.9 / 326.9 (M+H) + , RT=1.14 minutes.

[0475] Intermediate 2: Synthesis of 1-tetrahydropyran-2-yl-6-(2-tetrahydropyran-2-ylpyrazol-3-yl)indazole-4-carboxylic acid [ka] Step 1: Methyl 1-tetrahydropyran-2-yl-6-(2-tetrahydropyran-2-ylpyrazol-3-yl)indazole-4-carboxylate Methyl 6-bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylate Intermediate 1 (Step 1) (300 mg, 0.88 mmol), 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (295 mg, 1.06 mmol), and aqueous K2CO3 (1.2 M, 2.21 mL, 2.65 mmol) were mixed in 1,4-dioxane (6 mL), and the mixture was sparged with nitrogen for 5 minutes. 1,1'-Bis(di-tert-butylphosphanyl)ferrocene-dichloropalladium [Pd-118] (58 mg, 0.09 mmol) was added, and the mixture was sparged with nitrogen for an additional 5 minutes. The vessel was sealed, and the mixture was heated at 100 °C for 2 hours. The reaction mixture was cooled to room temperature, diluted with aqueous sodium bicarbonate (saturated, 30 ml), and extracted with ethyl acetate (2 x 50 ml). The combined organic extracts were washed with brine (4 x 30 ml), dried over sodium sulfate, and evaporated in vacuo. The residue was purified by silica gel chromatography (Biotage 25 g, eluting with 0-50% ethyl acetate / heptane) to give the title compound (291 mg, 79%) as a yellow foam. LCMS Method A (electrospray): m / z = 433.1 (M+H) + , RT=1.29 minutes.

[0476] Step 2: Intermediate 1 Using the method described in Step 2, the title compound was prepared and obtained as an off-white solid (175 mg, 62%). LCMS Method A (electrospray): m / z = 395.15 (M+H) + , RT=1.11 minutes.

[0477] Intermediate 3: Synthesis of 6-ethynyl-1-(oxan-2-yl)-1H-indazole-4-carboxylic acid [ka] Step 1: Methyl 1-tetrahydropyran-2-yl-6-(2-trimethylsilylethynyl)indazole-4-carboxylate [ka] Methyl 6-bromo-1-tetrahydropyran-2-yl-indazole-4-carboxylate (500 mg, 1.47 mmol), PdCl2(PPh3)2 (104 mg, 0.15 mmol), CuI (28 mg, 0.15 mmol), and triethylamine (1.03 mL, 7.37 mmol) were mixed in DMF (3 mL) and the mixture was sparged with nitrogen for 5 minutes. Ethynyl(trimethyl)silane (1.0 mL, 7.37 mmol) was added, the mixture was briefly sparged with nitrogen, and the vessel was sealed. The mixture was heated at 100 °C for 2.5 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (50 mL), and washed with saturated aqueous sodium bicarbonate (50 mL) and brine (5 × 50 mL). The organic layer was dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel chromatography [Biotage 50 g, eluted with 0-30% ethyl acetate / heptane] to give the title compound as a pale brown oil (553 mg (99% yield)). LCMS Method A (electrospray): m / z = 357.1 (M+H) + , RT=1.54 minutes.

[0478] Step 2: Intermediate 1 Using the method described in Step 2, the title compound was prepared from methyl 1-tetrahydropyran-2-yl-6-(2-trimethylsilylethynyl)indazole-4-carboxylate and obtained as a light brown solid (342 mg, 75%). LCMS Method A (electrospray): m / z = 270.95 (M+H) + , RT=1.10 minutes.

[0479] Intermediate 4: Synthesis of 4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid hydrochloride [ka] A suspension of methyl 4-oxopyrido[1,2-a]pyrimidine-2-carboxylate [Tetrahedron (2014), 70(17), 2761-2765] (5 g, 24.5 mmol) in THF (150 ml) was treated with potassium trimethylsilanolate (6.28 g, 49.0 mmol). The mixture was then added with HCl solution (15 ml of 4 M HCl in dioxane), heating was continued for 15 min, and then cooled to room temperature. The solid was collected by filtration, washed with diethyl ether, and dried under vacuum to give the title compound as a pale yellow solid (7.98 g, 86%) containing approximately 40% residual KCl. LCMS Method B (electrospray): m / z = 191.2 (M+H) + , RT=0.23 min.

[0480] Intermediate 5: Synthesis of 8-methoxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid [ka] Step 1: Methyl 8-methoxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylate [ka] To a vigorously stirred suspension of 4-methoxypyridin-2-amine (2 g, 16.1 mmol) in water (150 mL), dimethyl but-2-ynedioate (2.38 mL, 19.3 mmol) was slowly added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with DCM (100 mL) and allowed to stand at room temperature overnight. The phases were separated, and the aqueous phase was extracted with DCM (2 × 80 mL). The combined organic extracts were dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel chromatography (Biotage 50 g, eluting with 50–100% ethyl acetate / heptane) to give the crude product, which was triturated with ethyl acetate / heptane. The solid was collected by filtration and washed with heptane to give the title compound as a light brown solid (850 mg (23%)). LCMS Method B (electrospray): m / z = 235.2 (M+H)+ , RT=1.20 minutes.

[0481] Step 2: Intermediate 1 Using the method described in Step 2, the title compound was prepared from methyl 8-methoxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylate and obtained as a white solid (535 mg, 67%). LCMS Method B (electrospray): m / z = 221.2 (M+H) + , RT=0.31 min.

[0482] Intermediate 6: Synthesis of 7-chloro-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid [ka] The title compound was prepared from methyl 7-chloro-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxylate using the method described in Intermediate 1, Step 2 [Tetrahedron (2014), 70(17), 2761-2765] as a pale yellow solid (195 mg, 51%). LCMS Method B (electrospray): m / z = 225.1 (M+H) + , RT=0.31 min.

[0483] Intermediate 7: Synthesis of {7-bromoimidazo[1,2-a]pyridin-2-yl}methanamine [ka] Step 1: 2-[(7-bromoimidazo[1,2-a]pyridin-2-yl)methyl]isoindoline-1,3-dione [ka] A suspension of 4-bromopyridin-2-amine (2 g, 11.6 mmol) and 2-(3-bromo-2-oxopropyl)isoindoline-1,3-dione (3.26 g, 11.6 mmol) (U.S. Pat. No. 7,105,508, 2006) in ethanol (40 ml) was heated at reflux for 3 hours, during which time the material slowly dissolved and then precipitated. The mixture was cooled to room temperature, and the solid was collected by filtration, washed with MeOH, diethyl ether, and dried under vacuum to give the title compound as a white solid (3.09 g, 51%). LCMS Method B (electrospray): m / z = 356.1 / 358.1 (M+H) + , RT=1.49 minutes.

[0484] Step 2: {7-bromoimidazo[1,2-a]pyridin-2-yl}methanamine 2-[(7-Bromoimidazo[1,2-a]pyridin-2-yl)methyl]isoindoline-1,3-dione (3.09 g, 5.89 mmol) and hydrazine hydrate (2.9 mL, 59.0 mmol) were mixed in ethanol (40 mL), and the mixture was stirred at room temperature for 2 hours. The solid was collected by filtration, and the filtrate was allowed to stand overnight. Further solid was collected by filtration. The filtrate was evaporated directly onto silica gel (kp-NH), and the solid was loaded onto a short plug of kp-NH silica, and the system was eluted with 10% MeOH / DCM. Evaporation of the eluent afforded the title compound as a pale yellow solid (1.09 g, 72% yield). LCMS Method B: LC-MS (electrospray): m / z = 226.1 / 228.1 (M+H) + , RT=1.25 minutes.

[0485] Intermediate 8: Synthesis of {6-chloroimidazo[1,2-a]pyridin-2-yl}methanamine [ka] Step 1: 6-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine [ka] A suspension of 5-chloropyridin-2-amine (1.0 g, 7.78 mmol) and 1,3-dichloropropan-2-one (0.71 mL, 7.8 mmol) in ethanol (7.4 mL) was heated at 80 °C for 3 h. The mixture was cooled to room temperature and evaporated to dryness in vacuo. The residue was diluted with sodium bicarbonate (saturated, 20 mL) and extracted with DCM (3 × 15 mL). The combined organics were evaporated in vacuo, and the residue was purified by silica gel chromatography (Biotage; 50 g KPNH eluting with 0–100% ethyl acetate / heptane) to afford the title compound as an orange solid (435 mg, 28% yield). Method A: LC-MS (electrospray): m / z = 200.85 (M+H) + , RT=0.64 min.

[0486] Step 2: (6-chloroim...

Claims

1. Formula (I) 【Chemistry 1】 [During the ceremony, X is 【Chemistry 2】 [In the formula, R １ａ is hydrogen, halo, C １－６ Alkyl, C ２－３ Alkenyl and —O—C １－６ alkyl; R １ｂ is the following formula: -L １ａ -L １ｂ -Q １ {During the ceremony, L １ａ is absent or optionally substituted with one or more hydroxy １－３ alkylene; L １ｂ does not exist or R ｒ is hydrogen or C １－４ N(R ｒ ) and Q １ is C １－６ Alkyl, C ２－３ Alkenyl, C ３－６ is cycloalkyl, aryl, heterocyclyl, or heteroaryl; Here, the Q １ is halo, carboxy, trifluoromethyl, NR ｔ R ｕ , OR ｔ wherein R ｔ and R ｕ are independently hydrogen and C １－４ alkyl; or Q １ is one or more formulas: -L １ｃ -L １ｄ -Z １ (In the formula, L １ｃ does not exist; L １ｄ does not exist; Z １ is phenyl, 5- to 6-membered heteroaryl, C ３－８ Cycloalkyl (spirocyclic, carbocyclic and bridged C ３－８ cycloalkyl) or heterocyclyl (including monocyclic or bicyclic heterocyclic ring systems, spirocyclic heterocyclic ring systems or bridged heterocyclic ring systems); １ is C １－４ Alkyl, C ３－６ Cycloalkyl, heterocyclyl, halo, C １－４ Haloalkyl, OR ｔ１ , C(O)R ｔ１ , C(O)OR ｔ１ , O.C.(O.)R. ｔ１ wherein R ｔ１ and R ｕ１ are each independently hydrogen and C １－４ alkyl; Z １ is C ３－６ and optionally spiro-fused to a cycloalkyl or heterocyclyl ring. may be substituted with a group is a group of R １ａ’ is selected from hydrogen, halo, and methyl; R ２ａ is hydrogen] and Y is 【Transformation 3】 【Chemistry 4】 (In the formula, R ３ａ１ , R ３ｂ１ , R ３ｃ１ , R ３ｄ１ , R ３ｅ１ , R ３ｆ１ , R ３ｇ１ , R ３ｈ１ , R ３ｉ１ , R ３ｊ１ , R ３ｋ１ , R ３ｌ１ , R ３ｍ１ , R ３ｎ１ , R ３ｏ１ , R ３ｐ１ , R ３ｑ１ , R ３ｒ１ and R ３ｓ１ is selected from hydrogen and methyl, said methyl being optionally substituted with a hydroxy substituent; R ３ａ２ , R ３ｂ２ , R ３ｃ２ , R ３ｄ２ , R ３ｅ２ , R ３ｆ２ , R ３ｇ２ , R ３ｈ２ , R ３ｉ２ , R ３ｊ２ , R ３ｋ２ , R ３ｌ２ , R ３ｍ２ , R ３ｎ２ , R ３ｏ２ , R ３ｐ２ , R ３ｑ２ , R ３ｒ２ and R ３ｓ２ is hydrogen; n is 1 or 2) Selected from: Z is 【Transformation 5】 (In the formula, R ４ , R ７ , R ４ａ and R ７ａ is independently selected from hydrogen, halo, cyano, and methyl; R ５ , R ５ａ , R ５ｂ and R ５ｃ is independently selected from hydrogen, halo, cyano, and methyl; R ６ , R ８ , R ６ａ and R ８ａ is independently selected from hydrogen, halo, cyano, and methyl; R ９ , R ９ａ , R １０ and R １１ are independently hydrogen, NH ２ , halo, cyano and C １－６ alkyl; or R ９ and R １０ may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system, or R １０ and R １１ may be joined together to form a fused 5- or 6-membered saturated or unsaturated ring system; wherein either the fused 5- or 6-membered saturated or unsaturated ring system is １－２ -Alkyl, cyano, C １－２ Haloalkyl, hydroxy, C １－２ Alkoxy, Halo, C １－２ Haloalkoxy, NR １ｉａ R １ｊａ and -S(O) ０－２ R １ｉａ R １ｊａ wherein R １ｉａ and R １ｊａ is H or C １－２ is alkyl; R Ｚ１ and R Ｚ１ａ is hydrogen, C １－４ Alkyl, cyano, halo, C １－４ Haloalkyl, C １－４ Haloalkoxy, C １－４ Alkoxy, C ３－６ Cycloalkyl and —O—C ３－６ cycloalkyl, wherein said C ３－６ Cycloalkyl and —O—C ３－６ The cycloalkyl may be substituted with one or more halo, methyl, or methoxy; R Ｚ２ and R Ｚ２ａ is hydrogen, C １－４ Alkyl, cyano, halo, NH ２ and C １－４ alkoxy; R Ｚ３ａ is hydrogen, C １－４ Alkyl, cyano, halo, NH ２ and C １－４ alkoxy; A １ is CR １２ and N; A ２ is CR １３ and N; A ３ is CR １４ and N; A ４ is CR １５ and N; A ５ is CR １６ and N; A ６ is CR １７ and N; A ７ is CR １８ and N; A ８ is CR １９ R ２０ and N.R. ２１ Selected from: A ９ is CR ２２ R ２３ and N.R. ２４ Selected from: A １０ is CR ２５ R ２６ and N.R. ２７ Selected from: A １１ is CR ２８ R ２９ and N.R. ３０ Selected from: R １２ and R １４ are independently hydrogen, halo, cyano, and C １－４ alkyl; R １３ is selected from hydrogen, halo, cyano, methoxy, and methyl; R １５ is selected from hydrogen, halo, cyano, methoxy, and methyl; R １６ is hydrogen, halo, cyano, C １－４ Alkyl, C １－４ Alkoxy, C １－４ Haloalkyl, C １－４ Haloalkoxy, C ３－４ Cycloalkyl, 3- to 4-membered heterocyclyl and C ３－４ cycloalkoxy; R １７ is hydrogen, hydroxy, halo, cyano, C １－５ Alkyl, C １－４ Haloalkyl, C １－４ Alkoxy, C １－４ Haloalkoxy, C ２－４ Alkenyl, C ２－４ alkynyl, phenyl, 5- or 6-membered or heteroaryl, C ３－６ Cycloalkyl, —O—C ３－６ Cycloalkyl, heterocyclyl, -O-heterocyclyl(carbon bond), -(OCH ２ CH ２ ) ｍ -NR ｑ R ｒ , -(OCH ２ CH ２ ) ｍ -OCH ３ (wherein m is an integer of 1 to 6), NR ｑ R ｒ , —C(O)—NR ｑ R ｒ , -C(O)OR ｑ Selected from: Here, the R ｑ and R ｒ are each independently hydrogen, C １－５ Alkyl, C ３－６ cycloalkyl, 3- to 6-membered carbon-bonded heterocyclyl, wherein said C １－５ Alkyl, C ３－６ Cycloalkyl and 3- to 6-membered carbon-bonded heterocyclyl are C １－２ Alkyl, cyano, C １－２ Haloalkyl, hydroxy, C １－２ Alkoxy, Halo, C １－２ Haloalkoxy, NR １ｅａ R １ｆａ and -S(O) ０～２ R １ｅａ R １ｆａ wherein R １ｅａ and R １ｆａ is H or C １－２ is alkyl; or R ｑ and R ｒ together with the nitrogen atom to which they are attached, １－２ -Alkyl, cyano, C １－２ Haloalkyl, hydroxy, C １－２ Alkoxy, Halo, C １－２ may be joined together to form a 3- to 6-membered heterocyclic ring, which may be substituted with one or more substituents selected from haloalkoxy; Here, any of the C １－５ Alkyl, C １－４ Alkoxy, C ２－４ Alkenyl, C ２－４ alkynyl, phenyl, 5- or 6-membered or heteroaryl, C ３－６ Cycloalkyl, —O—C ３－６ Cycloalkyl, heterocyclyl or -O-heterocyclyl(carbon bond) is C １－２ Alkyl, cyano, C １－２ Haloalkyl, hydroxy, C １－２ Alkoxy, Halo, C １－２ Haloalkoxy, NR １ｅａ R １ｆａ or -S(O) ０－２ R １ｅａ R １ｆａ may be further substituted with one or more substituents selected from １ｅａ and R １ｆａ is H or C １－２ is alkyl; R １８ is hydrogen, halo, cyano, C １－４ Alkyl, C ２－４ Alkenyl, C ２－４ alkynyl, 5- or 6-membered heteroaryl, C １－４ Alkoxy, C １－４ Haloalkyl, C １－４ Haloalkoxy, C ３－４ Cycloalkyl, 3- to 4-membered heterocyclyl and C ３－４ -cycloalkoxy; R １９ , R ２０ , R ２５ and R ２６ is hydrogen, halo, cyano and C １－４ alkyl; R ２２ and R ２３ is selected from hydrogen, halo, cyano, and methyl; R ２８ and R ２９ is selected from hydrogen, methoxy and methyl; R ２１ , R ２４ , R ２７ and R ３０ is hydrogen) selected from Although it is a compound of However, the following compounds: 【Transformation 6】 【Transformation 7】 or a pharmaceutically acceptable salt thereof.

2. R １ａ 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein is selected from hydrogen, fluoro, bromo, methyl, ethenyl, and -O-methyl.

3. R １ｂ But the formula: -(CR １ｃ’ R １ｄ’ ) ｐ -NR １ｅ’ R １ｆ’ [During the ceremony, p is an integer selected from 1 and 2; R １ｃ’ and R １ｄ’ is independent, (i) hydrogen (including deuterium); (ii) C, optionally substituted with one or more hydroxy substituents １－３ Alkyl Selected from: R １ｅ’ is hydrogen (including deuterium) and C １－２ alkyl; R １ｆ’ is the formula: -(CR １ｇ R １ｈ ) ｑ -T １ (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R １ｇ and R １ｈ is independent, a) hydrogen (including deuterium); and b) cyano, hydroxy, C １－２ Alkoxy, halo and C １－２ C optionally substituted with one or more substituents selected from haloalkoxy １－２ Alkyl Selected from: T １ is C ３－８ cycloalkyl, aryl, heterocyclyl, heteroaryl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C ３－８ cycloalkyl or a bridged heterocyclic ring system, each of which is selected from C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo or C １－２ haloalkoxy) is a group of or R １ｅ’ and R １ｆ’ may be joined together with the nitrogen atom to which they are attached to form a monocyclic or bicyclic heterocyclic ring, and are １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo and C １－２ haloalkoxy; and / or R １ｅ’ and R １ｆ’ The monocyclic or bicyclic heterocyclic ring formed by ３－６ may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may be C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo and C １－２ haloalkoxy] 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

4. R １ｂ But the formula: -(CR １ｃ’ R １ｄ’ ) ｐ -NR １ｅ’ R １ｆ’ [During the ceremony, p is an integer selected from 1 and 2; R １ｃ’ and R １ｄ’ are independently hydrogen (including deuterium) and C １－２ alkyl; R １ｅ’ is hydrogen (including deuterium) and C １－２ alkyl; R １ｆ’ is the formula: -(CR １ｇ R １ｈ ) ｑ -T １ (In the formula, q is 0, 1, or 2 (e.g., q is 1 or 2); R １ｇ and R １ｈ are independently hydrogen (including deuterium) and C １－２ alkyl; T １ is C ３－４ Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C ３－８ cycloalkyl and bridged heterocyclic ring systems, each of which is selected from C １－２ -Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo or C １－２ haloalkoxy) is a group of or R １ｅ’ and R １ｆ’ are joined together with the nitrogen atom to which they are attached to form a monocyclic or bicyclic heterocyclic ring, and are C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo and C １－２ haloalkoxy; and / or R １ｅ’ and R １ｆ’ The monocyclic or bicyclic heterocyclic ring formed by ３－６ may be spiro-fused with a cycloalkyl or heterocyclic ring, which in turn may be C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxyhalo and C １－２ haloalkoxy] 4. The compound according to claim 1, wherein the compound is a group represented by the formula:

5. R １ｂ is the formula: -(CR １ｃ’ R １ｄ’ ) ｐ -NR １ｅ’ R １ｆ’ [During the ceremony, p is 1; R １ｃ’ and R １ｄ’ are independently hydrogen (including deuterium) or C １－２ alkyl; R １ｅ’ is hydrogen (including deuterium) or C １－２ alkyl; R １ｆ’ is the formula: -(CR １ｇ R １ｈ ) ｑ -T １ (In the formula, q is 1; R １ｇ and R １ｈ are independently hydrogen (including deuterium) or C １－２ alkyl; T １ is C ３－４ Cycloalkyl, heterocyclyl, spirocyclic carbocyclic or heterocyclic ring systems, bridged C ３－８ cycloalkyl or a bridged heterocyclic ring system, each of which is selected from C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo or C １－２ haloalkoxy) is the base of 5. The compound according to any one of claims 1 to 4, wherein the compound is a group represented by the formula: or a pharmaceutically acceptable salt thereof.

6. R １ｂ is methyl; 【Transformation 8】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, selected from:

7. R １ｂ but 【Chemistry 15】 The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, selected from:

8. Y is 【Chemistry 16】 [In the formula, n, R ３ａ１ , R ３ｂ１ , R ３ｅ１ , R ３ｉ１ , R ３ａ２ , R ３ｂ２ , R ３ｅ２ is as defined in claim 1. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, selected from:

9. R ３ａ１ , R ３ｂ１ , R ３ｃ１ , R ３ｄ１ , R ３ｅ１ , R ３ｆ１ , R ３ｇ１ , R ３ｈ１ , R ３ｉ１ , R ３ｊ１ , R ３ｋ１ , R ３ｌ１ , R ３ｍ１ , R ３ｎ１ , R ３ｏ１ , R ３ｐ１ , R ３ｑ１ , R ３ｒ１ and R ３ｓ１ The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein are independently hydrogen.

10. R ３ａ２ , R ３ｂ２ , R ３ｃ２ , R ３ｄ２ , R ３ｅ２ , R ３ｆ２ , R ３ｇ２ , R ３ｈ２ , R ３ｉ２ , R ３ｊ２ , R ３ｋ２ , R ３ｌ２ , R ３ｍ２ , R ３ｎ２ , R ３ｏ２ , R ３ｐ２ , R ３ｑ２ , R ３ｒ２ and R ３ｓ２ 10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

11. The compound according to any one of claims 1 to 10, wherein n is 1, or a pharmaceutically acceptable salt thereof.

12. Y is 【Chemistry 17】 12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, selected from:

13. Y is [Chemistry 18] 13. The compound according to any one of claims 1 to 12, wherein:

14. Z is 【Chemistry 19】 [In the formula, R ４ , R ５ , R ６ , R ７ , R ５ｃ , A １ , A ２ , A ３ , A ４ , R ８ , A ５ , A ６ , R Ｚ１ and R Ｚ２ is as defined in any one of claims 1 to 13.

14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, selected from:

15. R ４ , R ４ａ , R ５ , R ５ａ , R ５ｂ , R ５ｃ , R ６ , R ６ａ , R ７ , R ７ａ , R ８ , R ８ａ , R ９ , R １０ and R １１ The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

16. A １ is CR １２ and R １２ The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

17. A ２ is CR １３ and R １３ The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

18. A ３ is CR １４ and R １４ 18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein is hydrogen or chloro.

19. A ４ is CR １５ and R １５ The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein is hydrogen or methoxy.

20. A ５ is CR １６ and R １６ 20. The compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein is hydrogen.

21. A ６ is CR １７ and R １７ is hydrogen, halo, cyano, C １－４ Alkyl, C １－４ Haloalkyl, C １－４ Alkoxy, C １－４ Haloalkoxy, C ２－４ Alkenyl, C ２－４ Alkynyl, C ３－６ Cycloalkyl, —O—C ３－４ Cycloalkyl, heterocyclyl, -(OCH ２ CH ２ ) ｍ -OCH ３ (wherein m is 1, 2 or 3), NR ｑ R ｒ wherein R ｑ and R ｒ are each independently hydrogen or C １－２ is alkyl; Here, any of the C １－４ Alkyl, C ２－４ Alkenyl, C ２－４ Alkynyl, C ３－６ Cycloalkyl, —O—C ３－４ Cycloalkyl and heterocyclyl systems are C １－２ Alkyl, C １－２ Haloalkyl, cyano, hydroxy, C １－２ Alkoxy, halo and C １－２ 21. The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, which may be further substituted with one or more substituents selected from haloalkoxy.

22. R １７ is hydrogen, halo, C １－４ Alkoxy and C １－４ 22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, selected from haloalkoxy.

23. Z is 【Chemistry 20】 【Chemistry 21】 23. The compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, selected from:

24. X is 【Chemistry 22】 and Y is 【Chemistry 23】 Selected from: Z is 【Chemistry 24】 wherein R １ａ , R １ｂ , R １ａ’ , R ２ａ , R ３ａ１ , R ３ｉ１ , R ３ｌ１ , R ３ｒ１ , R ３ａ２ , R ３ｉ２ , R ３ｌ２ , R ３ｒ２ , n, R ４ , R ５ , R ６ , R ７ , R ５ｃ , A １ , A ２ , A ３ , A ４ , R ８ , A ５ and A ６ 2. The compound of claim 1, wherein:

25. X is 【Chemistry 25】 and Y is 【Chemistry 26】 and Z is 【Chemistry 27】 where R １ａ , R １ｂ , R １ａ’ , R ２ａ , R ３ａ１ , R ３ｉ１ , R ３ａ２ , R ３ｉ２ , n, A ５ and A ６ 25. The compound of claim 24, wherein: is as defined in claim 1, or a pharmaceutically acceptable salt thereof.

26. X is 【Chemistry 28】 and Y is 【Chemistry 29】 and Z is 【Transformation 30】 where R １ａ , R １ｂ , R １ａ’ , R ２ａ , R ３ａ１ , R ３ｉ１ , R ３ａ２ , R ３ｉ２ , n, A ３ , A ４ , R ７ and R ８ 25. The compound of claim 24, wherein: is as defined in claim 1, or a pharmaceutically acceptable salt thereof.

27. Any one of the following compounds or a pharmaceutically acceptable salt thereof: N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-chloroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-6-(1H-pyrazol-5-yl)-1H-indazole-4-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-bromo-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; 6-bromo-N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; 6-ethynyl-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({7-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyanoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 8-Methoxy-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-5-carboxamide; 7-chloro-N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-fluoroimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-methoxyimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({8-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-pyrazolo[4,3-c]pyridine-4-carboxamide; N-({7-bromoimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(2-hydroxy-1-{6-methylimidazo[1,2-a]pyridin-2-yl}ethyl)-1H-indazole-4-carboxamide; 4-(3-{imidazo[1,2-a]pyridin-2-yl}-2,5-dihydro-1H-pyrrole-1-carbonyl)-1H-indazole; N-[(6-{[(pyridin-3-yl)methyl]amino}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(1-methyl-1H-imidazol-4-yl)methyl]amino}imidazo[1,2a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-[[6-(3-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-({6-[(pyridin-3-yl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(piperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-{[6-(acetamidomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate; {6-methylimidazo[1,2-a]pyridin-2-yl}methyl 1H-indazole-4-carboxylate hydrochloride; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-hydroxyimidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(methylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide dihydrochloride; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-1H-indazole-4-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-formylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(aminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,2,2-trifluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[hydroxy(phenyl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-cyclopropylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({7-ethenylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 2-(1H-indazol-4-yl)-5-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]-1,3,4-oxadiazole; N-{[6-(2-aminoethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-butyl N-(2-{2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}ethyl)carbamate; N-benzyl-2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridine-6-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 7-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-amino-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]pyridine-3-carboxamide; N-({6-[(benzyloxy)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-7-methyl-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 8-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 6-bromo-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]quinoline-3-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]ethyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 6-chloro-N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-1H-indazole-4-carboxamide; 4-[5-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1,3,4-thiadiazol-2-yl]-1H-indazole; 4-[1-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; N-[(6-{[(3-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexyl-2-hydroxyethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(pyridin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-methoxyphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[benzyl(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1S)-1-phenylethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2-phenylpropan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4-fluorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(4,4,4-trifluorobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-4-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3,3,3-trifluoropropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(3-phenyloxetan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3-cyclopropylphenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-dimethylbutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(trifluoromethoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methanesulfonylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(3-phenylpyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylcyclopropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1,3-thiazol-5-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-butyl 3-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-{[6-({[(4,4-difluorocyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; tert-butyl 2-{[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]methyl}piperidine-1-carboxylate; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[2-(pyridin-3-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1,4-dioxan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclopropylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3,3-difluorocyclobutyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(oxetan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(1R,2R)-2-(trifluoromethyl)cyclopropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclohexylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4,4-difluorocyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({bicyclo[1.1.1]pentan-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2S)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(2R)-oxolan-2-yl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-difluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(oxolan-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-methylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(oxolan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 3-methyl-2-[({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amino]butanoate; N-[(6-{[(oxan-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(2S)-3,3,3-trifluoro-2-hydroxypropyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclobutylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(tert-butylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-fluoroethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(1,2,3,4-tetrahydroisoquinolin-2-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(diethylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(pyrrolidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(pyridin-2-yl)azetidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(dicyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopropylmethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[4-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[({spiro[2.2]pentan-1-yl}methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[3-(trifluoromethyl)piperidin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(5,5-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(3-methoxypropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(4,4-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-methylcyclopentyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(propylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-dimethyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(tert-butoxy)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-chlorophenyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(oxan-2-yl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-benzylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(4-phenoxypiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-difluorocyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2,2-dimethylcyclopropyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-methyloxolan-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-tert-butylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(4-tert-butylcyclohexyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopentylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[4-(2,2-dimethylpropanoyl)piperazin-1-yl]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-acetylpiperazin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({7-azabicyclo[2.2.1]heptan-7-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,2-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-{[(2,3,3-trimethylbutan-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(5-fluoropyridin-2-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[({[1,1'-bi(cyclopropan)]-1-yl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(2,6-dimethylmorpholin-4-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; Methyl 1-({2-[({4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}formamido)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)piperidine-3-carboxylate; N-[(6-{[(2-fluoro-2-methylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(1-cyclohexylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)(methyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(4-fluoro-4-methylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3,3-difluoropiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(1-hydroxycyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclopentylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(3,3-difluorocyclopentyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(cyclobutylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[2-(3,3-difluorocyclobutyl)ethyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2-fluorocyclobutyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({[(2S)-3,3-dimethylbutan-2-yl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-({6-azaspiro[2.5]octan-6-yl}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[({[(1r,3r)-3-fluorocyclobutyl]methyl}amino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(2-phenylethyl)amino]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(benzylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[2-(cyclohexylamino)ethyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-({6-[(phenylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylformamido)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-3-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-{[6-({[(piperidin-2-yl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{[(azetidin-3-yl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(cyclohexylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2-cyclopropylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-({6-[(piperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4H-chromene-2-carboxamide; N-{[6-({[(4-chlorophenyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-({6-[(benzylamino)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-{[6-({[(1-methylcyclohexyl)methyl]amino}methyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-chromene-2-carboxamide; N-[(6-{[(2,2-dimethylpropyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-chromene-2-carboxamide; 4-oxo-N-[(7-{[(2-phenylethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(7-{[(cyclopropylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[(6-{1-[(cyclohexylmethyl)amino]cyclopropyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-{[6-(2-amino-3-phenylpropyl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; (cyclohexylmethyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; N-(cyclohexylmethyl)-2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridine-6-carboxamide; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; 4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl][(3,3-difluorocyclobutyl)methyl]amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](2,2-dimethylpropyl)amine; [(2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl](cyclohexylmethyl)amine; 6-bromo-4-[1-({6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-1,2,3-triazol-4-yl]-1H-indazole; (2-{[4-(6-bromo-1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methanol; (2,2-dimethylpropyl)[(2-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)methyl]amine; ((cyclohexylmethyl)[1-(2-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}imidazo[1,2-a]pyridin-6-yl)ethyl]amine; (2,2-dimethylpropyl)({2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methyl)amine; {2-[(4-{1H-pyrazolo[3,4-c]pyridin-4-yl}-1H-1,2,3-triazol-1-yl)methyl]imidazo[1,2-a]pyridin-6-yl}methanol; N-({6-[(3R,5S)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-tert-butylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-1H-indazole-4-carboxamide; N-({6-[(3S,5R)-5-cyclohexylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-chromene-2-carboxamide; N-({6-[4-(2,2-dimethylpropyl)morpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-({6-[(3S,5R)-5-methylmorpholin-3-yl]imidazo[1,2-a]pyridin-2-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; and N-{[6-(9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-ol; 4-[1-[[6-[[(1-hydroxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-ol; 1-[[[2-[[4-(5-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[[[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclobutylmethyl)-1-[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-(cyclobutylmethyl)-1-[2-[[4-(5-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 4-[1-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]triazol-4-yl]-1H-indazol-3-amine N-[[6-[[(1-methoxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(1,4-oxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-cyano-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[3.3]heptan-2-ylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[2.3]hexan-5-ylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(1-bicyclo[1.1.1]pentanylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[(spiro[2.3]hexan-2-ylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-methoxy-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-methylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(butylaminomethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-hydroxycyclopentyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-methylbutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-cyclobutylethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2-hydroxy-2-methyl-propyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(1-hydroxycyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2-hydroxybutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3-methylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(3,3-dimethylcyclobutyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(2,2-dimethylbutylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(2S)-2-methylbutyl]amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[[[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; 1-[[[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carboxylic acid; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carboxamide; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-N,N-dimethyl-1H-indazole-6-carboxamide; [4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazol-6-yl]-morpholino-methanone; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-N-(2-hydroxyethyl)-1H-indazole-6-carboxamide; 1-[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 1-[[[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-[[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]-2,2-dimethyl-propan-1-amine; N-(cyclobutylmethyl)-1-[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; N-(cyclohexylmethyl)-1-[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; 1-[[[2-[[4-(7-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclopentanamine; N-[[6-[(4,4-dimethyl-1-piperidyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-5-fluoro-4-oxo-chromene-2-carboxamide; N-(cyclobutylmethyl)-1-[2-[[4-(6-morpholino-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 6-[2-(2-aminoethoxy)ethoxy]-N-[[6-[(4,4-dimethyl-1-piperidyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-[[6-[1-(cyclobutylmethylamino)-2-phenyl-ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[1-[bis(cyclobutylmethyl)amino]-2-phenyl-ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[2-[[4-(7-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-(cyclobutylmethyl)methanamine; 1-[[[2-[[4-(7-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; [2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanol N-(cyclobutylmethyl)-1-[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclohexylmethyl)-1-[2-[[4-(6-fluoro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-[[2-[[4-(6-cyclopropyl-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]-2,2-dimethyl-propan-1-amine; N-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-indazole-4-carboxamide; N-(cyclobutylmethyl)-1-[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-(cyclohexylmethyl)-1-[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(1H-pyrazolo[4,3-c]pyridin-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclobutanol; N-(cyclobutylmethyl)-1-[2-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 1-[[[2-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methylamino]methyl]cyclohexanol; 2-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]-6-methyl-imidazo[1,2-a]pyridine; N-[[6-[2-cyano-1-(cyclobutylmethylamino)ethyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(6-methylmorpholin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(7-bromo-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[(6-piperazin-2-ylimidazo[1,2-a]pyridin-2-yl)methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(6-cyclohexyl-4-oxo-2-piperidyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 1-[2-(1H-indazol-4-yl)thiazol-5-yl]-1-(6-methylimidazo[1,2-a]pyridin-2-yl)ethanol; 2-[[1-(1H-indazol-4-yl)triazol-4-yl]methyl]imidazo[1,2-a]pyridine; N-[(3,3-difluorocyclobutyl)methyl]-1-[2-[[1-(1H-indazol-4-yl)triazol-4-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 4-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-1H-indazole-6-carbonitrile; N-(cyclobutylmethyl)-1-[2-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; N-[[6-[[acetyl(cyclobutylmethyl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-(cyclobutylmethyl)-1-[2-[[3-(1H-indazol-4-yl)-1,2,4-triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine; 2-[1-[[6-[(cyclobutylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]pyrido[1,2-a]pyrimidin-4-one; N-[[6-[(2-bicyclo[2.2.1]hept-5-enylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(1R,2R,4S)-norbornan-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[[(1R,2S,4S)-norbornan-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-azabicyclo[2.2.1]heptan-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-(2-azabicyclo[2.2.2]octan-2-ylmethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[[(2,2-difluorospiro[3.3]heptan-6-yl)amino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[[[rac-(1S,2S,4S)-7-oxabicyclo[2.2.1]hept-5-en-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; 4-oxo-N-[[6-[[[rac-(1S,2R,4S)-7-oxabicyclo[2.2.1]hept-5-en-2-yl]methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide; and N-[(1-methoxycyclobutyl)methyl]-1-[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine.

28. 28. A pharmaceutical composition comprising a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

29. 29. A pharmaceutical composition according to claim 28 for use in therapy.

30. 29. The pharmaceutical composition of claim 28 for use in the treatment of a proliferative condition.

31. 29. The pharmaceutical composition of claim 28 for use in the treatment of cancer.

32. 29. The pharmaceutical composition of claim 28 for use in the treatment of leukemia.

33. 29. The pharmaceutical composition of claim 28 for use in the treatment of AML leukemia or chronic myeloid leukemia.

34. 29. The pharmaceutical composition of claim 28 for use in inhibiting METTL3 activity.

35. 29. The pharmaceutical composition of claim 28 for use in the treatment of an autoimmune, neurological, inflammatory or infectious disease.

36. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a proliferative condition.

37. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.

38. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of leukemia.

39. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of AML leukemia or chronic myeloid leukemia.

40. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an autoimmune disease, a neurological disease, an inflammatory disease, or an infectious disease.

41. 30. Use of a compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of METTL3 activity.

42. A combination comprising a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 27 together with one or more further therapeutic agents.

Images